COMMISSION DIRECTIVE 2000/32/EC
of 19 May 2000
adapting to technical progress for the 26th time Council Directive 67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (*)

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,


Whereas:

(1) Annex I to Directive 67/548/EEC contains a list of dangerous substances, together with particulars of the classification and labelling of each substance. Present scientific and technical knowledge has shown that the list of dangerous substances in that Annex should be adapted. Certain language versions of the Directive require corrections in specific sections of the foreword and of Table A to Annex I.


(3) Annex V to Directive 67/548/EEC lays down the methods for the determination of the physico-chemical properties, toxicity and ecotoxicity of substances and preparations. It is necessary to adapt that Annex to technical progress.

(4) Annex IX to Directive 67/548/EEC contains the provisions relating to child-proof fastenings. Those provisions should be adapted and updated. It is necessary to extend the scope of the use of child-proof fastenings.

(5) The measures provided for in this Directive are in accordance with the opinion of the Committee on the Adaptation to Technical Progress of the Directives for the Elimination of Technical Barriers to Trade in Dangerous Substances and Preparations,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Directive 67/548/EEC is hereby amended as follows:

1. Annex I is amended as follows:

(a) Note Q in Annex 1A to this Directive replaces the corresponding note in the Foreword.

(b) The rows in Annex 1B to this Directive replace the corresponding rows in Table A.

(c) The entries in Annex 1C to this Directive replace the corresponding entries.

(d) The entries in Annex 1D to this Directive are inserted.

2. The risk phrase in Annex 2 to this Directive replaces the corresponding phrase in Annex III.

3. Annex IV is amended as follows:

(a) The safety phrases in Annex 3A to this Directive replace the corresponding phrases in Annex IV.

(*) Adopted after the 27th adaptation.


(b) The combined safety phrases in Annex 3B to this Directive replace the corresponding phrases in Annex IV.

4. Part B of Annex V is amended as follows:

(a) The text in Annex 4A to this Directive replaces Chapter B.10.

(b) The text in Annex 4B to this Directive replaces Chapter B.11.

(c) The text in Annex 4C to this Directive replaces Chapter B.12.

(d) The text in Annex 4D to this Directive replaces Chapters B.13 and B.14.

(e) The text in Annex 4E to this Directive replaces Chapter B.17.

(f) The text in Annex 4F to this Directive replaces Chapter B.23. The title of Chapter B.23 in the explanatory note is changed accordingly.

(g) The text in Annex 4G to this Directive is added.

5. The fourth indent of the general introduction to Part C of Annex V is deleted.

6. The texts in Annex 5 to this Directive replace the corresponding texts in Annex VI.

7. Annex IX is amended as set out in Annex 6 to this Directive.

Article 2

1. Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive by 1 June 2001 at the latest. They shall forthwith inform the Commission thereof.

When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2. Member States shall communicate to the Commission the main provisions of national law which they adopt in the field covered by this Directive and a correlation table between this Directive and the national provisions adopted.

Article 3

This Directive shall enter into force on the third day following its publication in the Official Journal of the European Communities.

Article 4

This Directive is addressed to the Member States.

Done at Brussels, 19 May 2000.

For the Commission
Margot WALLSTROM
Member of the Commission
ANNEX 1A

FOREWORD TO ANNEX 1

Explanation of the notes relating to the identification, classification and labelling of substances

DA:

Note Q:

Klassificeringen som kræftfremkaldende kan udelades for fibre, som opfylder en af følgende betingelser:

— en kortvarig biopersistensprøve ved inhalation har vist, at fibre, der er længere end 20 µm, har en vægtet halveringstid på mindre end 10 dage

— en kortvarig biopersistensprøve ved intratrakeal instillation har vist, at fibre, der er længere end 20 µm, har en vægtet halveringstid på mindre end 40 dage

— en egnet intra-peritoneal prøve ikke har vist kræftfremkaldende virkning, eller

— en egnet langvarig inhalationsprøve ikke har vist relevante sygdomsfremkaldende virkninger eller neoplastiske forandringer.

SV:

Note Q:

Ämnet behöver inte klassificeras som cancerframkallande om det kan visas att det uppfyller ett av följande villkor:

— ett korttidstest för att bestämma den biologiska beständigheten vid inhalation har visat att fibrer längre än 20 µm

har en viktad halveringstid på mindre än 10 dagar

— ett korttidstest för att bestämma den biologiska beständigheten vid intratrakeal instillation har visat att fibrer längre

än 20 µm har en viktad halveringstid på mindre än 40 dagar

— ett lämpligt intraperitonealt test har inte givit belägg för förhöjd cancerogenitet

— frånvaro av relevant patogenitet eller neoplastiska förändringar i ett lämpligt långtids inhalationstest.

(Does not concern the ES version)
(Does not concern the DE version)
(Does not concern the EL version)
(Does not concern the EN version)
(Does not concern the FR version)
(Does not concern the IT version)
(Does not concern the NL version)
(Does not concern the PT version)
(Does not concern the FI version)
### ANNEX 1B

#### TABLE A

<table>
<thead>
<tr>
<th>Z</th>
<th>Symb.</th>
<th>ES</th>
<th>DA</th>
<th>DE</th>
<th>EL</th>
<th>EN</th>
<th>FI</th>
<th>FR</th>
<th>IT</th>
<th>NL</th>
<th>PT</th>
<th>SV</th>
</tr>
</thead>
<tbody>
<tr>
<td>'18</td>
<td>Ar</td>
<td>Argón</td>
<td>Argon</td>
<td>Argon</td>
<td>Arγό</td>
<td>Argon</td>
<td>Argon</td>
<td>Argon</td>
<td>Argon</td>
<td>Argon</td>
<td>Árgon</td>
<td>Argon'</td>
</tr>
<tr>
<td>'64</td>
<td>Gd</td>
<td>Gadolinio</td>
<td>Gadolinium</td>
<td>Γαδολίνιο</td>
<td>Gadolinium</td>
<td>Gadolinium</td>
<td>Gadolinium</td>
<td>Gadolinio</td>
<td>Gadolinium</td>
<td>Gadolinio</td>
<td>Gadolinium'</td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>---------------</td>
<td>-----------------------------</td>
<td>-------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>---------------------</td>
<td>-----------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-011-00-7</td>
<td>carbaryl (ISO) 1-naphthyl methylcarbamate</td>
<td></td>
<td>200-555-0</td>
<td>63-25-2</td>
<td>Carc. Cat. 3; R40 Xn: R22 N: R50</td>
<td>Xn: N R: 22-40-50 S: (2)22-24-36/37-46-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-015-00-9</td>
<td>diuron (ISO) 3-(3,4-dichlorophenyl)-1,1-dimethylurea</td>
<td></td>
<td>206-354-4</td>
<td>330-54-1</td>
<td>Carc. Cat. 3; R40 Mut. Cat. 3; R40 Xn: R22-48/22 N: R50-53</td>
<td>Xn: N R: 22-40-48/22-50/53 S: (2)13-22-23-37-46-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-016-00-4</td>
<td>propoxur (ISO) 2-isopropoxyphenyl N-methylcarbamate 2-isopropoxyphenyl methylcarbamate</td>
<td></td>
<td>204-043-8</td>
<td>114-26-1</td>
<td>T: R25 N: R50-53</td>
<td>T: N R: 25-50/53 S: (1/2)37-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-019-00-0</td>
<td>di-allate (ISO) S-(2,3-dichloroallyl)-N,N-diisopropylthiocarbamate</td>
<td></td>
<td>218-961-1</td>
<td>2303-16-4</td>
<td>Carc. Cat. 3; R40 Xn: R22 N: R50-53</td>
<td>Xn: N R: 22-40-50/53 S: (2)25-36/37-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>-------</td>
<td>--------------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>-----------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-026-00-9</td>
<td>carbofuran (ISO) 2,3-dihydro-2,2-dimethylbenzofuran-7-yl N-methylcarbamate</td>
<td></td>
<td>216-353-0</td>
<td>1563-66-2</td>
<td>T+; R26/28 N; R50-53</td>
<td>T+; N</td>
<td>R: 26/28-50/53 S: (1/2)-36/37-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-028-00-X</td>
<td>dinobuton (ISO) 2-[(1-methylpropyl)-4,6-dinitrophenyl isopropyl carbonate</td>
<td></td>
<td>213-546-1</td>
<td>973-21-7</td>
<td>T; R25 N; R50-53</td>
<td>T; N</td>
<td>R: 25-50/53 S: (1/2)-37-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-029-00-5</td>
<td>dioxacarb (ISO) 2-[(1,3-dioxolan-2-yl)phenyl N-methylcarbamate</td>
<td></td>
<td>230-253-4</td>
<td>6988-21-2</td>
<td>T; R25 N; R51-53</td>
<td>T; N</td>
<td>R: 25-51/53 S: (1/2)-37-45-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-031-00-7</td>
<td>metoxuron (ISO) 3-(3-chloro-4-methoxyphenyl)-1,1-dimethyleurea</td>
<td></td>
<td>243-433-2</td>
<td>19937-59-8</td>
<td>N; R50-53 N</td>
<td>N</td>
<td>R: 50/53 S: 60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-034-00-2</td>
<td>pebulate (ISO) N-butyl-N-ethyl-S-propylthiocarbamate</td>
<td></td>
<td>214-215-4</td>
<td>1114-71-2</td>
<td>Xn; R22 N; R51-53</td>
<td>Xn; N</td>
<td>R: 22-51/53 S: (2)-23-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-035-00-8</td>
<td>pirimicarb (ISO) 5,6-dimethyl-2-dimethylamino-pyrimidin-4-yl N,N-dimethylcarbamate</td>
<td></td>
<td>245-430-1</td>
<td>23103-98-2</td>
<td>T; R25 N; R50-53</td>
<td>T; N</td>
<td>R: 25-50/53 S: (1/2)-22-37-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-037-00-9</td>
<td>promecarb (ISO) 3-isopropyl-3-methylphenyl N-methylcarbamate</td>
<td></td>
<td>220-113-0</td>
<td>2631-37-0</td>
<td>T; R25 N; R50-53</td>
<td>T; N</td>
<td>R: 25-50/53 S: (1/2)-24-37-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-038-00-4</td>
<td>sulfallate (ISO) 2-chlorallyl N,N-dimethylthiocarbamate</td>
<td></td>
<td>E</td>
<td>202-388-9</td>
<td>Carc. Cat. 2; R45 Xn; R22 N; R50-53</td>
<td>T; N</td>
<td>R: 45-22-50/53 S: 53-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-039-00-0</td>
<td>tri-allate (ISO) S-2,3,3-trichlorallyl diisopropylthiocarbamate</td>
<td></td>
<td>218-962-7</td>
<td>2303-17-5</td>
<td>Xn; R22-48/22 R43 N; R50-53</td>
<td>Xn; N</td>
<td>R: 22-43-48/22-50/53 S: (2)-24-37-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-042-00-6</td>
<td>monuron (ISO) 3-(4-chlorophenyl)-1,1-dimethyleurea</td>
<td></td>
<td>205-766-1</td>
<td>150-68-5</td>
<td>Carc. Cat. 3; R40 Xn; R22 N; R50-53</td>
<td>Xn; N</td>
<td>R: 22-40-50/53 S: (2)-36/37-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-043-00-1</td>
<td>monuron-TCA 3-(4-chlorophenyl)-1,1-dimethyluronium trichloroacetate</td>
<td></td>
<td>—</td>
<td>140-41-0</td>
<td>Xn; R36/38 Carc. Cat. 3; R40 N; R50-53</td>
<td>Xn; N</td>
<td>R: 36/38-40-50/53 S: (2)-36/37-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>------------</td>
<td>----------------</td>
<td>-------------------</td>
<td>---------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-045-00-2</td>
<td>methomyl (ISO) 1-(methylthio)ethylideneamino N-methylcarbamate</td>
<td></td>
<td>240-815-0</td>
<td>16752-77-5</td>
<td>T+; R28</td>
<td>N: R50-53</td>
<td>T+: N</td>
<td>R: 28-50/53 S: (1/2)-22-36/37-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-046-00-8</td>
<td>bendiocarb (ISO) 2,2-dimethyl-1,3-benzodioxol-4-yl N-methylcarbamate</td>
<td></td>
<td>245-216-8</td>
<td>22781-23-3</td>
<td>T; R23/25</td>
<td>Xn: R21</td>
<td>T: N</td>
<td>R: 21-23/25-50/53 S: (1/2)-22-36/37-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-048-00-9</td>
<td>ethiofencarb (ISO) 2-(ethylthiomethyl)phenyl N-methylcarbamate</td>
<td></td>
<td>249-981-9</td>
<td>29973-13-5</td>
<td>Xn; R22</td>
<td>N: R50-53</td>
<td>Xn: N</td>
<td>R: 22-50/53 S: (2)-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-050-00-X</td>
<td>fenuron-TCA 1,1-dimethyl-3-phenyluronium trichloroacetate</td>
<td></td>
<td>—</td>
<td>4482-55-7</td>
<td>Xi; R38</td>
<td>N: R50-53</td>
<td>Xi: N</td>
<td>R: 38-50/53 S: (2)-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-053-00-6</td>
<td>isoprocarb (ISO) 2-isopropylphenyl N-methylcarbamate</td>
<td></td>
<td>220-114-6</td>
<td>2631-40-5</td>
<td>Xn; R22</td>
<td>N: R50-53</td>
<td>Xn: N</td>
<td>R: 22-50/53 S: (2)-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-060-00-4</td>
<td>oxycarboxin (ISO) 2,3-dihydro-6-methyl-5-(N-phenylcarbamoyl)-1,4-oxothiine 4,4-dioxide</td>
<td></td>
<td>226-066-2</td>
<td>5259-88-1</td>
<td>Xn; R22</td>
<td>R52-53</td>
<td>Xn: R</td>
<td>R: 22-52/53 S: (2)-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-069-00-3</td>
<td>thiophanate-methyl (ISO) 1,2-di(-3-methoxy carbonyl)-2-thioureido)benzene</td>
<td></td>
<td>245-740-7</td>
<td>23564-05-8</td>
<td>Muta. Cat. 3; R40</td>
<td>N: R50-53</td>
<td>Xn: N</td>
<td>R: 40-50/53 S: (2)-36/37-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>006-070-00-9</td>
<td>furmecyclox N-cyclohexyl-N-methoxy-2,5-dimethyl-3-furamide</td>
<td></td>
<td>262-302-0</td>
<td>60568-05-0</td>
<td>Carc. Cat. 3; R40</td>
<td>N: R50-53</td>
<td>Xn: N</td>
<td>R: 40-50/53 S: (2)-36/37-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>---------------</td>
<td>-----------------------------</td>
<td>-------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>---------------------</td>
<td>-----------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>007-012-00-5</td>
<td>N,N-dimethylhydrazine 1,1-dimethylhydrazine</td>
<td>E</td>
<td>200-316-0</td>
<td>57-14-7</td>
<td>T: R11</td>
<td>F: T; N R: 45-11-23/25-34-51/53</td>
<td>S: 53-45-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>007-013-00-0</td>
<td>N,N-dimethylhydrazine 1,2-dimethylhydrazine</td>
<td>E</td>
<td>—</td>
<td>540-73-8</td>
<td></td>
<td>C: 25%: T; R45-23/24/25 3%≤C&lt;25%: T; R45-20/21/22 0.01%≤C&lt;3%: T; R45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>009-003-00-1</td>
<td>hydrofluoric acid ... %</td>
<td>B</td>
<td>231-634-8</td>
<td>7664-39-3</td>
<td>T+: R26/27/28 C: R35</td>
<td>T+: C R: 26/27/28-35 S: (1/2)-7/9-26-36/37-45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>016-013-00-X</td>
<td>sulphur dichloride</td>
<td>234-129-0</td>
<td>10545-99-0</td>
<td>R14 C: R34 N: R50</td>
<td>C: N R: 14-34-50 S: (1/2)-26/36/39-45-61</td>
<td>C: 10%: C; R34 5%≤C&lt;10%: Xi; R36/37/38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>----------------</td>
<td>----------------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>--------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>016-014-00-5</td>
<td>sulphur tetrachloride</td>
<td></td>
<td>—</td>
<td>13451-08-6</td>
<td>C; N</td>
<td>R: 14-34-50</td>
<td>C Φ 10%: C; R34 5% ≤ C &lt; 10%: Xi; R36/37/38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>016-023-00-4</td>
<td>dimethyl sulphate</td>
<td>E</td>
<td>201-058-1</td>
<td>77-78-1</td>
<td>R: 22-50/53</td>
<td>S: (1/2)-26-36/37/39-45-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>016-024-00-X</td>
<td>dimexano (ISO) bis(methoxythiocarbonyl) disulphide</td>
<td></td>
<td>215-993-8</td>
<td>1468-37-7</td>
<td>R43</td>
<td>Xi; R: 22-50/53</td>
<td>C Φ 25%: T; R45-25-26-34-43 10% ≤ C &lt; 25%: T; R45-22-26-34-43 7% ≤ C &lt; 10%: T; R45-22-26-34-43/38-43 5% ≤ C &lt; 7%: T; R45-22-23-36/37/38-43 3% ≤ C &lt; 5%: T; R45-22-23-43 1% ≤ C &lt; 3%: T; R45-23-43 0,1% ≤ C &lt; 1%: T; R45-20 0,01% ≤ C &lt; 0,1%: T; R45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>016-071-00-6</td>
<td>trisodium-3-amino-6,13-dichloro-10-((3-(4-chloro-6-(2-sulfophenylamino)-1,3,5-triazin-2-yl)amino)propyl)amino)-4,11-triphenoxidoazinedisulfonate</td>
<td></td>
<td>410-130-3</td>
<td>136248-03-8</td>
<td>R43</td>
<td>Xi; R: 43</td>
<td>C Φ 10%: C; R34 5% ≤ C &lt; 10%: Xi; R36/37/38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>022-001-00-5</td>
<td>titanium tetrachloride</td>
<td></td>
<td>231-441-9</td>
<td>7550-45-0</td>
<td>R14</td>
<td>C Φ 14-34</td>
<td>C Φ 10%: C; R34 5% ≤ C &lt; 10%: Xi; R36/37/38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>050-002-00-0</td>
<td>cyhexatin (ISO) hydroxytricyclohexylstannane tri(cyclohexyl)tin hydroxide</td>
<td></td>
<td>236-049-1</td>
<td>13121-70-5</td>
<td>Xn; R20/21/22</td>
<td>Xn: N</td>
<td>F: C; N; R: 20/21/22-50/53 S: (2)-13-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------------------------</td>
<td>-----------------------------</td>
<td>-------------</td>
<td>----------------</td>
<td>----------------</td>
<td>---------------</td>
<td>-----------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>050-017-00-2</td>
<td>fenbutatin oxide (ISO)</td>
<td></td>
<td>236-407-7</td>
<td>13356-08-6</td>
<td>T+; R26</td>
<td>T+; N</td>
<td>R: 26-36/38-50/53</td>
<td>S: (1/2-)28-36/37-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>bis(tris(2-methyl-2-phenylpropyl)tin)oxide</td>
<td></td>
<td></td>
<td></td>
<td>Xi; R36/38 R50/53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>082-009-00-X</td>
<td>lead sulfochromate yellow</td>
<td></td>
<td>215-693-7</td>
<td>1344-37-2</td>
<td>Carc. Cat. 3; R40 Repr. Cat. 1; R61 Repr. Cat. 3; R62 R33 N: R50-53</td>
<td>T; N R: 61-33-40-50/53 S: 53-45-60-61</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C.I. Pigment Yellow 34 [This substance is identified in the Colour Index by Colour Index Constitution Number, C.I. 77603.]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>082-010-00-5</td>
<td>lead chromate molybdate sulfate red</td>
<td></td>
<td>235-759-9</td>
<td>12656-85-8</td>
<td>Carc. Cat. 3; R40 Repr. Cat. 1; R61 Repr. Cat. 3; R62 R33 N: R50-53</td>
<td>T; N R: 61-33-40-50/53 S: 53-45-60-61</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C.I. Pigment red 104. [This substance is identified in the Colour Index by Colour Index Constitution Number, C.I. 77605.]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>601-032-00-3</td>
<td>benzo[a]pyrene</td>
<td></td>
<td>200-028-5</td>
<td>50-32-8</td>
<td>Carc. Cat.2; R45 Muta. Cat. 2; R46 Repr. Cat. 2; R60-61 N: R50-53</td>
<td>T; N R: 45-46-60-61-50/53 S: 53-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>benzo[de]chryosene</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>601-034-00-4</td>
<td>benz[e]acephenanthrylene</td>
<td></td>
<td>205-911-9</td>
<td>205-99-2</td>
<td>Carc. Cat.2; R45 N: R50-53</td>
<td>T; N R: 45-50/53 S: 53-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>602-035-00-2</td>
<td>1,4-dichlorobenzene</td>
<td></td>
<td>203-400-5</td>
<td>106-46-7</td>
<td>Xi: R36 N: R50-53</td>
<td>Xi: N R: 36-50/53 S: (2-)24/25-46-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>602-054-00-6</td>
<td>3-iodopropene</td>
<td></td>
<td>209-130-4</td>
<td>556-56-9</td>
<td>R10 C: R34</td>
<td>C R: 10-34 S: (1/2-)7-26-45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------</td>
<td>---------------</td>
<td>----------------</td>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-076-00-9</td>
<td>but-2-yne-1,4-diol 2-butyne-1,4-diol</td>
<td>203-788-6</td>
<td>110-65-6</td>
<td>T: R23/25</td>
<td>T: R: 21-23/25-34-48/22</td>
<td>Ca 50%: T; R21-23/25-34-48/22 25%≤C&lt;50%: T; R21-23/25-36/38-48/22 10%≤C&lt;25%: Xn; R20/22/48/22 3%≤C&lt;10%: Xn; R20/22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-091-00-0</td>
<td>exo-1-methyl-4-(1-methylethyl)-7-oxabicyclo[2.2.1]heptan-2-ol</td>
<td>402-470-6</td>
<td>87172-89-2</td>
<td>O: R8</td>
<td>O: Xn R: 8-22-36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-093-00-1</td>
<td>exo- (+/-)-1-methyl-4-(1-methylethyl)-2-[2-methylphenylmethoxy]-7-oxabicyclo[2.2.1]heptane</td>
<td>402-410-9</td>
<td>87818-31-3</td>
<td>Xn; R20</td>
<td>Xn: N R: 20-51/53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-097-00-3</td>
<td>1,1’,1”-nitrotripropan-2-ol triisopropanolamine</td>
<td>204-528-4</td>
<td>122-20-3</td>
<td>X: R36</td>
<td>Xi: R: 36-52/53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-117-00-0</td>
<td>propan-2-ol isopropanol</td>
<td>200-661-7</td>
<td>67-63-0</td>
<td>F: R11</td>
<td>F: Xi R: 11-36-67</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-020-00-6</td>
<td>biphenyl-2-ol 2-hydroxybiphenyl 2-phenylphenol (ISO)</td>
<td>201-993-5</td>
<td>90-43-7</td>
<td>X: R36/37/38</td>
<td>X: N R: 36/37/38-50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-021-00-1</td>
<td>2-phenylphenol, sodium salt sodium 2-biphenylate</td>
<td>205-055-6</td>
<td>132-27-4</td>
<td>X: R22</td>
<td>X: R37/38-41 N: R50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-024-00-8</td>
<td>4,4’-isobutyldenediphenol (alt): 2,2-bis(4-hydroxyphenyl)-4-methylpentane</td>
<td>401-720-1</td>
<td>6807-17-6</td>
<td>Repr. Cat. 2; R60</td>
<td>X: R36/37/38-41 N: R50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>--------</td>
<td>--------</td>
<td>----------------</td>
<td>----------</td>
<td>----------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-043-00-1</td>
<td>monobenzone 4-hydroxyphenyl benzyl ether hydroquinone monobenzyl ether</td>
<td></td>
<td>203-083-3</td>
<td>103-16-2</td>
<td>Xi; R36 R43</td>
<td>Xi</td>
<td>R: 36-43</td>
<td>S: (2)-24/25-26-37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-044-00-7</td>
<td>mequinol 4-methoxyphenol hydroquinone monomethyl ether</td>
<td></td>
<td>205-769-8</td>
<td>150-76-5</td>
<td>Xn: R22 R36 R43</td>
<td>Xn</td>
<td>R: 22-36-43</td>
<td>S: (2)-24/25-26-37/39-46</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>605-016-00-7</td>
<td>glyoxal ... % ethanolial ... %</td>
<td>B</td>
<td>203-474-9</td>
<td>107-22-2</td>
<td>Muta. Cat. 3; R40 Xn: R20 Xr: R36/38 R43</td>
<td>Xn</td>
<td>R: 20-36/38-40-43</td>
<td>S: (2)-36/37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td>Xi; R36/38 R43</td>
<td>R: 22-36-43</td>
<td>S: (2)-24/25-26-37/39-46</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>606-018-00-0</td>
<td>dichlone (ISO) 2,3-dichloro-1,4-naphthoquinone</td>
<td></td>
<td>204-210-5</td>
<td>117-80-6</td>
<td>Xn: R22 Xr: R36/38 N: R50-53</td>
<td>Xn:</td>
<td>N</td>
<td>R: 22-26-40-50/53 S: (2)-26-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>606-019-00-6</td>
<td>chlordecone (ISO) perchloropentacyclo[5,3,0,0²,6,0³,0⁴,0⁸] decan-5-one</td>
<td></td>
<td>205-601-3</td>
<td>143-50-0</td>
<td>Carc. Cat. 3; R40 T: R24/25 N: R50-53</td>
<td>T:</td>
<td>N</td>
<td>R: 24/25-40-50/53 S: (1/2)-32-36-37-45-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>606-034-00-8</td>
<td>metribuzin (ISO) 4-amino-6-tort-butyl-3-methylthio-1,2,4-triazin-5(4H)-one</td>
<td></td>
<td>244-209-7</td>
<td>21087-64-9</td>
<td>Xn: R22 N: R50-53</td>
<td>Xn:</td>
<td>N</td>
<td>R: 22-50/53 S: (2)-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>606-035-00-3</td>
<td>chloridazon (ISO) 5-amino-4-chloro-2-phenylpyridazine-3-(2H)-one pyrazon</td>
<td></td>
<td>216-920-2</td>
<td>1698-60-8</td>
<td>R43 N: R50-53</td>
<td>Xi: N</td>
<td>R: 43-50/53</td>
<td>S: (2)-24-37-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>606-037-00-4</td>
<td>triadimefon (ISO) 1-(4-chloro)oxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butanone</td>
<td></td>
<td>256-103-8</td>
<td>43121-43-3</td>
<td>Xn: R22 N: R51-53</td>
<td>Xn: N</td>
<td>R: 22-51/53</td>
<td>S: (2)-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>---------------</td>
<td>----------------------------</td>
<td>-------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>606-044-00-2</td>
<td>2,4,6-trimethylbenzophenone</td>
<td>403-150-9</td>
<td>954-16-5</td>
<td>Xn; R22</td>
<td>X: R36 N: R50-53</td>
<td>X: N R: 22-36-50/53 S: (2-26-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-043-00-X</td>
<td>dicamba (ISO) 2,3-dichloro-6-methoxybenzoic acid 3,6-dichloro-2-methoxybenzoic acid</td>
<td>217-635-6</td>
<td>1918-00-9</td>
<td>Xn; R22</td>
<td>X: R41 R52-53</td>
<td>X: N R: 22-41-52/53 S: (2-26-60-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-057-00-6</td>
<td>coumachlor (ISO) 3-[1-(4-chlorophenyl)-3-oxobutyl]-4-hydroxy-coumarin</td>
<td>201-378-1</td>
<td>81-82-3</td>
<td>Xn: R48/22 R52-53</td>
<td>Xn R: 48-22-52/53 S: (2-37-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-079-00-6</td>
<td>kelevan (ISO) ethyl-5-(perchloro-5-hydroxypentacyclo(5,3,0,0,2,6,0,3,9,0,4,8)decan-5-yl)-4-oxopentanoate ethyl-5-(1,2,3,5,6,7,8,9,10,10-decachloro-4-hydroxypentacyclo(5,2,1,0,2,6,0,3,9,0,5,8)dec-4-yl)-4-oxovalerate</td>
<td>—</td>
<td>4234-79-1</td>
<td>T: R24 Xn: R22 N: R51-53</td>
<td>T N R: 22-24-51/53 S: (1/2-36-37-45-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-097-00-4</td>
<td>benzene-1,2,4-tricarboxylic acid 1,2-anhydride trimellitic anhydride</td>
<td>209-008-0</td>
<td>552-30-7</td>
<td>X: R37-41 R42/43</td>
<td>Xn R: 37-41-42/43 S: (2-22-26-36/37/39</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-143-00-3</td>
<td>valeric acid</td>
<td>203-677-2</td>
<td>109-52-4</td>
<td>C: R34 R52-53</td>
<td>C R: 34-52/53 S: (1/2-26-36-45-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-152-00-2</td>
<td>2,3,6-TBA (ISO) 2,3,6-trichlorobenzoic acid</td>
<td>200-026-4</td>
<td>50-31-7</td>
<td>X: R22 N: R51-53</td>
<td>X: N R: 22-51/53 S: (2-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-153-00-8</td>
<td>benazolin (ISO) 4-chloro-2,3-dihydro-2-oxo-1,3-benzothiazol-3-ylacetic acid</td>
<td>223-297-0</td>
<td>3813-05-6</td>
<td>X: R36/38 R52-53</td>
<td>X R: 36-38-52/53 S: (2-22-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>---------</td>
<td>-----------</td>
<td>----------------</td>
<td>---------------</td>
<td>----------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-159-00-0</td>
<td>chlorobenzilate (ISO) ethyl 2,2-di(4-chlorophenyl)-2-hydroxacetate ethyl-4,4'-dichlorobenzilate</td>
<td></td>
<td>208-110-2</td>
<td>510-15-6</td>
<td>Xn: R22</td>
<td>N: R50-53</td>
<td>Xn: N R: 22-50/53 S: (2)-360/61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-176-00-3</td>
<td>A mixture of: (($\alpha$-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-$\omega$-hydroxypropoxy(oxyethylene))$\alpha$-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-$\omega$-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionylpoxypolyoxypoly (oxyethylene))</td>
<td></td>
<td>400-830-7</td>
<td>—</td>
<td>R43</td>
<td>N: R51-53</td>
<td>Xn: N R: 43-51/53 S: (2)-36/37-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-213-00-3</td>
<td>ethyl-3,3-bis[(1,1-dimethylpropyl)peroxy] butyrate</td>
<td></td>
<td>403-320-2</td>
<td>67567-23-1</td>
<td>E: R2</td>
<td>O: R7 R10</td>
<td>N: R51-53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-217-00-5</td>
<td>2-ethoxyethyl-2-[4-(2,6-dihydro-2,6-dioxo-7-phenyl-1,5-dioxindacen-3-yl]phenoxyacetate</td>
<td></td>
<td>403-960-2</td>
<td>—</td>
<td>R43</td>
<td>R53</td>
<td>Xi R: 43-53 S: (2)-24-37-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-248-00-4</td>
<td>naptalam-sodium sodium N-naphth-1-ylphthalamate</td>
<td></td>
<td>205-073-4</td>
<td>132-67-2</td>
<td>Xn: R22</td>
<td></td>
<td>Xn R: 22 S: (2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[1] 3,6-dichloro-o-anisic acid, compound with 2,2’-iminodietanol (1:1) [2] 3,6-dichloro-o-anisic acid, compound with 2-aminoethanol (1:1) [3]
<table>
<thead>
<tr>
<th>Index No</th>
<th>Chemical name</th>
<th>Notes related to substances</th>
<th>EC No</th>
<th>CAS No</th>
<th>Classification</th>
<th>Labelling</th>
<th>Concentration limits</th>
<th>Notes related to preparations</th>
</tr>
</thead>
<tbody>
<tr>
<td>607-249-00-X</td>
<td>(1-methyl-1,2-ethanediyl)bis(oxy(methyl-2,1-ethanediyl))diacrylate tripropylene glycol diacrylate TPGDA</td>
<td></td>
<td>256-032-2</td>
<td>42978-66-5</td>
<td>Xi: R36/37/38</td>
<td>Xi: N</td>
<td>R: 36/37/38-43/51/53</td>
<td>S: (2)-24-37-61</td>
</tr>
<tr>
<td>607-255-00-2</td>
<td>fluroxypyr (ISO) 4-amino-3,5-dichloro-6-fluoro-2-pyridyloxycetic acid</td>
<td></td>
<td>—</td>
<td>69377-81-7</td>
<td>R52-53</td>
<td>R: 52/53</td>
<td>S: 61</td>
<td></td>
</tr>
<tr>
<td>608-016-00-5</td>
<td>1,4-Dicyano-2,3,5,6-tetra-chloro-benzene</td>
<td></td>
<td>401-550-8</td>
<td>1897-41-2</td>
<td>R43</td>
<td>N: R50-53</td>
<td>Xi: N</td>
<td>R: 43-50/53</td>
</tr>
<tr>
<td>609-040-00-9</td>
<td>nitrofen (ISO) 2,4-dichlorophenyl 4-nitrophenyl ether</td>
<td></td>
<td>217-406-0</td>
<td>1836-75-5</td>
<td>Carc. Cat. 2: R45</td>
<td>Repr. Cat. 2: R61</td>
<td>Xn: R22</td>
<td>N: R50-53</td>
</tr>
<tr>
<td>609-044-00-0</td>
<td>tecnazene (ISO) 1,2,4,5-tetrachloro-3-nitrobenzene</td>
<td></td>
<td>204-178-2</td>
<td>117-18-0</td>
<td>Xn: R22</td>
<td>R43</td>
<td>N: R50-53</td>
<td>Xi: N</td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>--------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>611-008-00-4</td>
<td>4-aminoazobenzene 4-phenylazoaniline</td>
<td></td>
<td>200-453-6</td>
<td>60-09-3</td>
<td>Carc. Cat. 2; R45 N; R50-53</td>
<td>T; N R: 45-50/53 S: 53-43-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>611-013-00-1</td>
<td>trilithium 1-hydroxy-7-(3-sulfonatoanilino)-2-(3-methyl-4-(2-methoxy-4-(3-sulfonatophenylazo)phenylazo) naphthalene-3-sulfonate</td>
<td></td>
<td>403-650-7</td>
<td>117409-78-6</td>
<td>E; R2 N; R51-53</td>
<td>E: N R: 2-51/53 S: (2)35-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>611-031-00-X</td>
<td>4,4′-(4-iminocylohexa-2,5-dienylidenemethylen)diolidilin hydrochloride C.I. Basic Red 9</td>
<td></td>
<td>209-321-2</td>
<td>569-61-9</td>
<td>Carc. Cat. 2; R45</td>
<td>T R: 45 S: 53-45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-035-00-4</td>
<td>2-methoxyaniline o-anisidine</td>
<td>E</td>
<td>201-963-1</td>
<td>90-04-0</td>
<td>Carc. Cat. 2; R45 Mut. Cat. 3; R40 T; R23/24/25</td>
<td>T R: 45-23/24/25 S: 53-45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-042-00-2</td>
<td>benzidine 1,1′-byphenyl-4,4′-diamine 4,4′-diaminobiphenyl biphenyl-4,4′-ylenediamine</td>
<td>E</td>
<td>202-199-1</td>
<td>92-87-5</td>
<td>Carc. Cat. 1; R45 Xn; R22 N; R50-53</td>
<td>T N R: 45-22-50/53 S: 53-43-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-051-00-1</td>
<td>4,4′-diaminodiphenylmethane 4,4′-methylenediamine</td>
<td>E</td>
<td>202-974-4</td>
<td>101-77-9</td>
<td>Carc. Cat. 2; R45 Mut. Cat. 3; R40 T; R39/23/24/25Xn; R48/20/21/22 R43 N: R51-53</td>
<td>T N R: 45-39/23/24/25-43-48/20/21/22-51/53 S: 53-45-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-081-00-5</td>
<td>salts of 4,4′-bi-α-toluidine salts of 3,3′-dimethylbenzidine salts of α-toluidine</td>
<td>A E</td>
<td>210-322-5</td>
<td>263-294-7 277-985-0</td>
<td>612-82-8 64969-36-4 74753-18-7</td>
<td>Carc. Cat. 2; R45 Xn; R22 N; R51-53</td>
<td>T N R: 45-39/23/24/25/48/20/21/22-51/53 S: 53-45-61</td>
<td></td>
</tr>
<tr>
<td>612-099-00-3</td>
<td>4-methyl-m-phenylenediamine 2,4-toluenediamine</td>
<td>E</td>
<td>202-453-1</td>
<td>95-80-7</td>
<td>Carc. Cat. 2; R45 T; R25 Xn; R21 Xi; R36 R43 N: R51-53</td>
<td>T N R: 45-21-25/36-43-51/53 S: 53-45-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-105-00-4</td>
<td>2-piperazin-1-ylethylamine</td>
<td></td>
<td>205-411-0</td>
<td>140-31-8</td>
<td>Xn, R21/22 C; R34 R43 R52-53</td>
<td>C R: 21/22-34-43-52/53 S: (1/2)-26-36/37/39-45-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>-------</td>
<td>-------------</td>
<td>----------------</td>
<td>-------------------------------</td>
<td>----------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>612-111-00-7</td>
<td>2-methyl-m-phenylenediamine 2,6-toluenediamine</td>
<td></td>
<td>212-513-9</td>
<td>823-40-5</td>
<td>Muta. Cat. 3; R40 Xn; R21/22 R43 N; R51-53</td>
<td>Xn; N R: 21/22-40-43-51/53 S: (2-)24-36/37-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-125-00-3</td>
<td>2-methyl-p-phenylenediamine 2,5-toluenediamine</td>
<td></td>
<td>202-442-1</td>
<td>95-70-5</td>
<td>T: R25 Xn; R20/21 R43 N; R51-53</td>
<td>T: N R: 20/21-25-43-51/53 S: (1/2-)24-37-45-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-144-00-7</td>
<td>flumetralin (ISO) N-(2-chloro-6-fluorobenzyl)-N-ethyl-α,α,α- trifluoro-2,6-dinitro-p-toluidine</td>
<td></td>
<td>—</td>
<td>62924-70-3</td>
<td>Xi; R36/38 R43 N; R50-53</td>
<td>Xi; N R: 36/38-43-50/53 S: (2-)36/37-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-151-00-5</td>
<td>diaminotoluene</td>
<td>E</td>
<td>246-910-3</td>
<td>25376-45-8</td>
<td>Carc. Cat. 2; R45 T: R25 Xn; R20/21 R43 N; R51-53</td>
<td>T: N R: 45-20/21-25-36-43-51/53 S: 53-43-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>613-018-00-4</td>
<td>morfamquat (ISO) 1,1’-bis(3,5-dimethylmorpholinocarbonyl-methyl)-4,4’-bipyridilium ion</td>
<td></td>
<td>—</td>
<td>7411-47-4</td>
<td>Xn; R22 Xn; R36/37/38 R52-53</td>
<td>Xn R: 22-36/37-38/52/53 S: (2-)22-36-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>613-031-00-5</td>
<td>symclosene trichloroisocyanuric acid trichloro-1,3,5-triazinetron</td>
<td></td>
<td>201-782-8</td>
<td>87-90-1</td>
<td>O: R8 Xn; R22 R31 Xn; R36/37 N; R50-53</td>
<td>O: Xn; N R: 8-22-31-36/37-50/53 S: (2-)8-26-41-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>613-038-00-3</td>
<td>6-phenyl-1,3,5-triazine-2,4-diyldiamine 6-phenyl-1,3,5-triazine-2,4-diamine benzoguanamine</td>
<td></td>
<td>202-095-6</td>
<td>91-76-9</td>
<td>Xn; R22 R52-53</td>
<td>Xn R: 22-52/53 S: (2-)61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>613-042-00-5</td>
<td>imazalil (ISO) 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole</td>
<td></td>
<td>252-615-0</td>
<td>35554-44-0</td>
<td>Xn; R20/22 N; R41 N; R50-53</td>
<td>Xn; N R: 20/22-41-50/53 S: (2-)26-39-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------------------</td>
<td>----------------------------</td>
<td>-------</td>
<td>------------</td>
<td>----------------</td>
<td>-----------</td>
<td>---------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>613-066-00-6</td>
<td>terbumeton (ISO) 2-tert-butylamino-4-ethylamino-6-methoxy-1,3,5-triazin</td>
<td></td>
<td>251-637-8</td>
<td>33693-04-8</td>
<td>Xn: R22</td>
<td>N: R50-53</td>
<td>Xn: N</td>
<td>R: 22-50/53</td>
</tr>
<tr>
<td>613-098-00-0</td>
<td>N-(n-octyl)-2-pyrrolidinone</td>
<td></td>
<td>403-700-8</td>
<td>2687-94-7</td>
<td>C: R34</td>
<td>N: R51-53</td>
<td>C: N</td>
<td>R: 34-51/53</td>
</tr>
<tr>
<td>613-130-00-3</td>
<td>hexaconazole (ISO) (RS)-2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol</td>
<td>—</td>
<td>—</td>
<td>79983-71-4</td>
<td>R43</td>
<td>N: R51-53</td>
<td>Xi: N</td>
<td>R: 22-52/53</td>
</tr>
<tr>
<td>613-131-00-9</td>
<td>pyroquilon (ISO) 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one</td>
<td>—</td>
<td>—</td>
<td>57369-32-1</td>
<td>Xn: R22</td>
<td>R52-53</td>
<td>Xn: R: 22-52/53</td>
<td>S: (2)-24-37-61</td>
</tr>
<tr>
<td>613-134-00-5</td>
<td>myclobutanil (ISO) 2-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)hexanenitrile</td>
<td>—</td>
<td>—</td>
<td>88671-89-0</td>
<td>Repr. Cat. 3: R63 Xn: R22 Xi: R36 N: R51-53</td>
<td>Xn: N</td>
<td>R: 22-36-51/53-63</td>
<td>S: (2)-36-37-46-61</td>
</tr>
<tr>
<td>613-137-00-1</td>
<td>methabenziiazuron (ISO) 1-(1,3-benzothiazol-2-yl)1,3-dimethylurea</td>
<td></td>
<td>242-505-0</td>
<td>18691-97-9</td>
<td>N: R50-53</td>
<td>N</td>
<td>R: 50/53</td>
<td>S: 60-61</td>
</tr>
<tr>
<td>613-139-00-2</td>
<td>metsulfuron-methyl methyl 2-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl) benzoate</td>
<td>—</td>
<td>—</td>
<td>74223-64-6</td>
<td>N: R50-53</td>
<td>N</td>
<td>R: 50/53</td>
<td>S: 60-61</td>
</tr>
<tr>
<td>614-006-00-1</td>
<td>brucine 2,3-dimethoxystrychnine</td>
<td></td>
<td>206-614-7</td>
<td>357-57-3</td>
<td>T+: R26/28 RS52-53</td>
<td>T+</td>
<td>R: 26/28-52/53</td>
<td>S: (1/2)-13-45-61</td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>-------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>616-010-00-9</td>
<td>tosylchloramide sodium</td>
<td></td>
<td>204-854-7</td>
<td>127-65-1</td>
<td></td>
<td>Xn; R22 R31 C; R34 R42</td>
<td>C R: 22-31-34-42 S: (1/2)-7-22-26-36/37/39-45</td>
<td></td>
</tr>
<tr>
<td>616-034-00-X</td>
<td>pyracarbolid (ISO) 3,4-dihydro-6-methyl-2H-pyran-5-carboxanilide</td>
<td></td>
<td>246-419-4</td>
<td>24691-76-7</td>
<td>R52-53</td>
<td></td>
<td>R: 52/53 S: 61</td>
<td></td>
</tr>
<tr>
<td>617-004-00-9</td>
<td>1,2,3,4-tetrahydro-1-naphthyl hydroperoxide</td>
<td></td>
<td>212-230-0</td>
<td>771-29-9</td>
<td>O: R7 Xn: R22 C: R34 N: R50-53</td>
<td>O: C N R: 7-22-34-50/53 S: (1/2)-3/7-14-26 -36/37/39-45-60-61</td>
<td>C ≤ 25%: C; R22-34 10%≤C&lt;25%: C; R34 5%≤C&lt;10%: Xi; R36/37/38</td>
<td></td>
</tr>
<tr>
<td>617-008-00-0</td>
<td>dibenzoyl peroxide benzoyl peroxyde</td>
<td></td>
<td>202-327-6</td>
<td>94-36-0</td>
<td>E: R2 Xn: R36 R43</td>
<td>E: Xi; R: 2-36-43 S: (2)-3/7-14-36/37/39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>650-007-00-3</td>
<td>chlordimeform (ISO) N'-4-Chlor-o-toly-N,N'-dimethylformamidine</td>
<td></td>
<td>228-200-5</td>
<td>6164-98-3</td>
<td>Carc. Cat. 3; R40 Xn: R21/22 N: R50-53</td>
<td>Xn: N R: 21/22-40/50/53 S: (2)-22-36/37-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------------------------------------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------------</td>
<td>-----------</td>
<td>--------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>650-041-00-9</td>
<td>triasulfuron (ISO) 1-[2-(2-chloroethoxy)phenylsulfonyl]-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)urea</td>
<td>—</td>
<td>82097-50-5</td>
<td>N: R50-53</td>
<td>N</td>
<td>R: 50/53 S: 60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>-----------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>006-090-00-8</td>
<td>2-(3-iodoprop-2-yn-1-yloxy)ethyl phenylcarbamate</td>
<td></td>
<td>408-010-0</td>
<td>88558-41-2</td>
<td>Xn: R20</td>
<td>Xi: R41</td>
<td>R52-53</td>
<td></td>
</tr>
<tr>
<td>014-016-00-0</td>
<td>A mixture of: 1,3-dihex-5-en-1-yl-1,1,3,3-tetramethyldisiloxane; 1,3-dihex-n-en-1-yl-1,1,3,3-tetramethyldisiloxane</td>
<td></td>
<td>406-490-6</td>
<td>—</td>
<td>N: R51-53</td>
<td>R: 20-41-52/53</td>
<td>S: (2-)22-26-39-61</td>
<td></td>
</tr>
<tr>
<td>015-164-00-9</td>
<td>calcium-P,P’-(1-hydroxyethylene)bis(hydrogenphosphonate)dihydrate</td>
<td></td>
<td>400-480-5</td>
<td>36669-85-9</td>
<td>R52-53</td>
<td>R: 52/53</td>
<td>S: 61</td>
<td></td>
</tr>
<tr>
<td>015-163-00-4</td>
<td>A mixture of: thiobis(4,1-phenylene)-S,S,S',S'-tetraphenyldisulfoniumhexafluorophosphate; diphenyl(4-phenylthiophenyl)sulfonium hexafluorophosphate</td>
<td></td>
<td>404-986-7</td>
<td>—</td>
<td>Xi: R41</td>
<td>N: R50-53</td>
<td>S: 60-61</td>
<td></td>
</tr>
<tr>
<td>015-166-00-X</td>
<td>3,9-bis(2,6-di-tert-butyl-4-methylphenoxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane</td>
<td></td>
<td>410-290-4</td>
<td>80693-00-1</td>
<td>R53</td>
<td>R: 53</td>
<td>S: 61</td>
<td></td>
</tr>
<tr>
<td>015-167-00-5</td>
<td>3-(hydroxyphenylphosphinyl)propanoic acid</td>
<td></td>
<td>411-200-6</td>
<td>14657-64-8</td>
<td>Xi: R41</td>
<td>N: 41</td>
<td>S: (2-)26-39</td>
<td></td>
</tr>
<tr>
<td>601-050-00-1</td>
<td>benzene, C_{10-13}-alkyl derivatives</td>
<td></td>
<td>267-051-0</td>
<td>67774-74-7</td>
<td>N: R50</td>
<td>N: 50</td>
<td>S: 61</td>
<td></td>
</tr>
<tr>
<td>601-051-00-7</td>
<td>4-phenylbut-1-ene</td>
<td></td>
<td>405-980-7</td>
<td>768-56-9</td>
<td>Xi: R38</td>
<td>N: R51-53</td>
<td>N: 38-51/53</td>
<td>S: (2-)37-61</td>
</tr>
<tr>
<td>602-084-00-X</td>
<td>1,1-dichloro-1-fluoroethane</td>
<td></td>
<td>404-080-1</td>
<td>1717-00-6</td>
<td>N: R52-53-59</td>
<td>N: 52/53-59</td>
<td>S: 59-61</td>
<td></td>
</tr>
<tr>
<td>603-128-00-0</td>
<td>2-(phenylmethoxy)naphthalene</td>
<td></td>
<td>405-490-3</td>
<td>613-62-7</td>
<td>R53</td>
<td>R: 53</td>
<td>S: 61</td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Notes related to preparations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------</td>
<td>--------------------------</td>
<td>----------------</td>
<td>----------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-129-00-6</td>
<td>1-tert-butoxypropan-2-ol</td>
<td>406-180-0</td>
<td>57018-52-7</td>
<td>R10</td>
<td>Xi; R41</td>
<td>R: 10-41 S: (2-)26-39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-130-00-1</td>
<td>A mixture of isomers of: α-((dimethyl)biphenyl)-ω-hydroxypropyloxyethylene</td>
<td>406-325-8</td>
<td>—</td>
<td>Xn; R22</td>
<td>R52-53</td>
<td>Xn R: 22-52/53 S: (2-)39-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-131-00-7</td>
<td>A 3:1 mixture of: 1-deoxy-1-[methyl-(1-oxododecyl)amino]-D-glucitol; 1-deoxy-1-[methyl-(1-oxotetradecyl)amino]-D-glucitol</td>
<td>407-290-1</td>
<td>—</td>
<td>Xi; R41</td>
<td></td>
<td>Xi R: 41 S: (2-)26-39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-132-00-2</td>
<td>2-hydroxymethyl-9-methyl-6-(1-methylethyl)-1,4-dioxaspiro[4.5]decane</td>
<td>408-200-3</td>
<td>63187-91-7</td>
<td>Xi; R38-41</td>
<td>R52-53</td>
<td>Xi R: 38-41-52/53 S: (2-)26-37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-133-00-8</td>
<td>A mixture of: 3-[(4-amino-2-chloro-5-nitrophenyl)amino]-propane-1,2-diol; 3,3'-[(2-chloro-5-nitro-1,4-phenylenediimino)bis(propan-1,2-diol)</td>
<td>408-240-1</td>
<td>—</td>
<td>Xn; R22</td>
<td>R52-53</td>
<td>Xn R: 22-52/53 S: (2-)22-36-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-134-00-3</td>
<td>A mixture of substituted dodecyl and/or tetradecyl, diphenyl ethers. The substance is produced by the Friedel Crafts reaction. The catalyst is removed from the reaction product. Diphenyl ether is substituted by C1-C10 alkyl groups. The alkyl groups are bonded randomly between C1 and C6. Linear C12 and C14, 50/50 used.</td>
<td>410-450-3</td>
<td>—</td>
<td>R53</td>
<td></td>
<td>R: 53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-135-00-9</td>
<td>bis[[2,2',2''-nitritotris[ethanolate]-1-N,O]bis[2-(2-methoxyethoxy)ethoxy]-titanium</td>
<td>410-500-4</td>
<td>—</td>
<td>Xi; R41</td>
<td>N; R51-53</td>
<td>Xi; N R: 41-51/53 S: (2-)26-39-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-137-00-X</td>
<td>A mixture of: 1-deoxy-1-[methyl-(1-oxohexadecyl)amino]-D-glucitol; 1-deoxy-1-[methyl-(1-oxo-octadecyl)amino]-D-glucitol</td>
<td>411-130-6</td>
<td>—</td>
<td>Xi; R41</td>
<td></td>
<td>Xi R: 41 S: (2-)26-39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>603-138-00-5</td>
<td>3-[2,2-dimethyl-3-hydroxypropyl]toluene alt.: 2,2-dimethyl-3-(3-methylphenyl)propanol</td>
<td>403-140-4</td>
<td>103694-68-4</td>
<td>R52-53</td>
<td></td>
<td>R: 52/53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>------------</td>
<td>------------</td>
<td>----------------</td>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td></td>
</tr>
<tr>
<td>604-050-00-X</td>
<td>4-chloro-o-cresol 4-chloro-2-methyl phenol</td>
<td>216-381-3</td>
<td>1570-64-5</td>
<td>T; R23</td>
<td>N</td>
<td>C ≥ 25%; T; C R23-35 10% ≤ C &lt; 25% C; R20-35 5% ≤ C &lt; 10% C; R20-34 3% ≤ C &lt; 5% C; R20-36/37/38 1% ≤ C &lt; 3% C; Xi; R36/37/38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-051-00-5</td>
<td>3,5-bis(3,5-di-tert-butyl-4-hydroxybenzyl)-2,4,6-trimethylphenol</td>
<td>401-110-5</td>
<td>87113-78-8</td>
<td>R52-53</td>
<td>R</td>
<td>C ≤ 52/53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-052-00-0</td>
<td>2,2’-methylenebis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutylphenol)</td>
<td>403-800-1</td>
<td>103597-45-1</td>
<td>R53</td>
<td>R</td>
<td>C ≤ 53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-053-00-6</td>
<td>2-methyl-4-(1,1-dimethylethyl)-6-(1-methylpentadecyl)-phenol</td>
<td>410-760-9</td>
<td>157661-93-3</td>
<td>Xi; R38</td>
<td>R</td>
<td>C ≤ 38-43-50/53 S: (2-)24-37-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-054-00-1</td>
<td>2-methoxy-4-(tetrahydro-4-methylene-2H-pyran-2-yl)-phenol;4-(3,6-dihydro-4-methyl-2H-pyran-2-yl)-2-methoxyphenol</td>
<td>412-020-0</td>
<td>—</td>
<td>R43</td>
<td>R</td>
<td>C ≤ 43-52/53 S: (2-)24-37-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>604-055-00-7</td>
<td>A mixture of: 2-methoxy-4-(tetrahydro-4-methylene-2H-pyran-2-yl)-phenol;4-(3,6-dihydro-4-methyl-2H-pyran-2-yl)-2-methoxyphenol</td>
<td>413-900-7</td>
<td>85954-11-6</td>
<td>Mutacat:3; R40</td>
<td>X</td>
<td>C ≤ 40 S: (2-)22-36-37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>605-027-00-7</td>
<td>A mixture of: 3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-indene-6-carboxaldehyde; 3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-indene-5-carboxaldehyde</td>
<td>410-480-7</td>
<td>—</td>
<td>R43</td>
<td>N</td>
<td>C ≤ 43-51/53 S: (2-)24-37-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>606-051-00-0</td>
<td>4-pentylocyclohexanone</td>
<td>406-670-4</td>
<td>61203-83-6</td>
<td>N</td>
<td>R</td>
<td>N ≤ 51/53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>606-052-00-6</td>
<td>4-(N,N-dibutylamino)-2-hydroxy-2’-carboxybenzophenone</td>
<td>410-410-5</td>
<td>54574-82-2</td>
<td>R52-53</td>
<td>R</td>
<td>C ≤ 52/53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
</tr>
<tr>
<td>----------</td>
<td>---------------</td>
<td>-----------------------------</td>
<td>-------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>607-273-00-0</td>
<td>ammonium-7-(2,6-dimethyl-8-(2,2-dimethylbutyryloxy)-1,2,6,7,8,8a-hexahydro-1-naphthyl)-3,5-dihydroxyheptanoate</td>
<td></td>
<td>404-520-2</td>
<td>—</td>
<td>R52-53</td>
<td>R: 52/53</td>
<td>S: 61</td>
<td></td>
</tr>
<tr>
<td>607-274-00-6</td>
<td>2-(N-benzyl-N-methylamino)ethyl-3-amino-2-butenoate</td>
<td></td>
<td>405-350-1</td>
<td>54527-73-0</td>
<td>R43 N: R51-53</td>
<td>Xi: N R: 43-51/53 S: (2-)24-37-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-275-00-1</td>
<td>sodium benzyloxybenzene-4-sulfonate</td>
<td></td>
<td>405-450-5</td>
<td>66531-87-1</td>
<td>R43</td>
<td>Xi R: 43 S: (2-)24-37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-276-00-7</td>
<td>bis[(1-methylimidazol)-(2-ethyl-hexanoate)], zinc complex</td>
<td></td>
<td>405-635-0</td>
<td>—</td>
<td>Xi: R38-41 N: R50-53</td>
<td>Xi: N R: 38-41-50/53 S: (2-)26-37/39-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-278-00-8</td>
<td>A mixture of isomers of sodium phenethylphenalenesulfonate; sodium naphthylethylbenzenesulfonate</td>
<td></td>
<td>405-760-0</td>
<td>—</td>
<td>Xi: R41 R43 R52-53</td>
<td>Xi R: 41-43-52/53 S: (2-)24-26-37/39-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-279-00-3</td>
<td>A mixture of n-octadecylaminodiethyl bis(hydrogenmaleat); n-octadecylaminodiethyl hydrogen maleate hydrogenphthalate</td>
<td></td>
<td>405-960-8</td>
<td>—</td>
<td>R43 N: R51-53</td>
<td>Xi: N R: 43-51/53 S: (2-)24-37-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-280-00-9</td>
<td>sodium 4-chloro-1-hydroxybutane-1-sulfonate</td>
<td></td>
<td>406-190-5</td>
<td>54322-20-2</td>
<td>Xn: R22 Xn: R36 R43</td>
<td>Xn R: 22-36-43 S: (2-)22-26-36/37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-281-00-4</td>
<td>A mixture of branched and linear C7-C9 alkyl 3-[3-(2H-benzotriazol-2-yl)-5-(1,1-dimethyl-ethyl)-4-hydroxyphenyl]propionates</td>
<td></td>
<td>407-000-3</td>
<td>127519-17-9</td>
<td>N: R51-53</td>
<td>N R: 51/53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-282-00-X</td>
<td>2-acetoxymethyl-4-benzyloxybut-1-yl acetate</td>
<td></td>
<td>407-140-5</td>
<td>131266-10-9</td>
<td>R52-53</td>
<td>R: 52/53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>--------</td>
<td>-----------------</td>
<td>----------------</td>
<td>--------------------</td>
<td>------------------------------------------------------------</td>
<td>-------------------------------</td>
<td></td>
</tr>
<tr>
<td>607-283-00-5</td>
<td>E-ethyl-4-oxo-4-phenylcrotonate</td>
<td>408-040-4</td>
<td>15121-89-8</td>
<td>Xn; R21/22</td>
<td>Xi; R38-41</td>
<td>R43</td>
<td>N; R50-53</td>
<td></td>
</tr>
<tr>
<td>607-284-00-0</td>
<td>A 9:1 mixture of: sodium 3,3’-(1,4-phenylenebis(carbonylimino)-3,1-propanediylinino)bis(10-amino-6,13-dichloro)-4,11-triphenodioxazinedisulfonate; lithium 3,3’-(1,4-phenylenebis(carbonylimino)-3,1-propanediylinino)bis(10-amino-6,13-dichloro)-4,11-triphenodioxazinedisulfonate</td>
<td>410-040-4</td>
<td>136213-76-8</td>
<td>N; R51-53</td>
<td>N</td>
<td>R: 21/22-38-41-43-50/53</td>
<td>S: (2-)26-36/37/39-60-61</td>
<td></td>
</tr>
<tr>
<td>607-285-00-6</td>
<td>A mixture of: 7-((3-aminophenyl)sulfonylamino)naphthalene-1,3-disulfonic acid;sodium 7-((3-aminophenyl)sulfonylamino)naphthalene-1,3-disulfonate; potassium7-((3-aminophenyl)sulfonylamino)naphthalene-1,3-disulfonate</td>
<td>410-065-0</td>
<td>—</td>
<td>R43</td>
<td>Xi</td>
<td>R: 43</td>
<td>S: (2-)22-24-37</td>
<td></td>
</tr>
<tr>
<td>607-287-00-7</td>
<td>O’-methyl O-(1-methyl-2-methacyloyloxy-ethyl)-1,2,3,6-tetrahydrophthalate</td>
<td>410-140-8</td>
<td>—</td>
<td>R52-53</td>
<td>R: 52/53</td>
<td></td>
<td>S: 52/53</td>
<td></td>
</tr>
<tr>
<td>607-288-00-2</td>
<td>Tetrasodium (c-3-1-3-6-dichloro-5-cyanopyrimidin-1-yl(methyl)amino) propyl)-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo)-4-sulfonatophenylsulfamoyl)Lphthalocyanine a,b,d-trisulfonato(6-)]nickelato (II), where a is 1 or 2 or 3 or 4, b is 8 or 9 or 10 or 11, c is 15 or 16 or 17 or 18, d is 22 or 23 or 24 or 25 and where e and f together are 2 and 4 or 2 and 2 respectively.</td>
<td>410-160-7</td>
<td>148732-74-5</td>
<td>Xi; R36</td>
<td>R43</td>
<td>R52-53</td>
<td>Xi: R: 36-43-52/53</td>
<td>S: (2-)22-26-36/37-61</td>
</tr>
<tr>
<td>607-288-00-8</td>
<td>3-3-(4,2,4-bis(1,1-dimethylpropyl)phenoxylbutylaminocarbonyl-4-hydroxy-1-naphthalenyl)thio)propanoic acid</td>
<td>410-370-9</td>
<td>105488-33-3</td>
<td>R53</td>
<td>R: 53</td>
<td>S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-290-00-3</td>
<td>A mixture (ratio not known) of: ammonium 1-C14-C18-alkoxy carbonyl-2-(3-alloxy-2-hydroxypropoxy carbonyl)ethane-1-sulfonate; ammonium 2-C14-C18-alkoxy carbonyl-1-(3-alloxy-2-hydroxypropoxy carbonyl)ethane-1-sulfonate</td>
<td>410-540-2</td>
<td>—</td>
<td>Xi; R38</td>
<td>R43</td>
<td>N: R50-53</td>
<td>Xi: N</td>
<td>R: 38-43-50/53</td>
</tr>
<tr>
<td>607-291-00-9</td>
<td>dodecyl-u-(C5/C6-cycloalkyl)alkyl carboxylate</td>
<td>410-630-1</td>
<td>104051-92-5</td>
<td>R53</td>
<td>R: 53</td>
<td>S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>--------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>607-292-00-4</td>
<td>A mixture of: [1-(methoxymethyl)-2-(C12-alkoxy)-ethoxy]acetic acid; [1-(methoxymethyl)-2-(C14-alkoxy)-ethoxy]acetic acid</td>
<td></td>
<td>410-640-6</td>
<td>—</td>
<td>Xi; R38-41 N; R50-53</td>
<td>Xi; N R: 38-41-50/53 S: (2-)26-37/39-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-293-00-X</td>
<td>A mixture of: N-aminoethylpiperazonium mono-2,4,6-trimethylnonyldiphenyl ether di-sulfonate; N-aminoethylpiperazonium di-2,4,6-trimethylnonyldiphenyl ether di-sulfonate</td>
<td></td>
<td>410-650-0</td>
<td>—</td>
<td>Xi; R41 R43 N; R51-53</td>
<td>Xi; N R: 41-43-51/53 S: (2-)26-36/37/39-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-294-00-5</td>
<td>sodium 2-benzoyloxy-1-hydroxyethane-sulfonate</td>
<td></td>
<td>410-680-4</td>
<td>—</td>
<td>R43</td>
<td>Xi R: 43 S: (2-)24-37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-295-00-0</td>
<td>A mixture of: hexasodium phosphonobutane-1,2,3,4-tetraacrylate; hexasodium phosphonobutane-1,2,3,4-tetraacrylate</td>
<td></td>
<td>410-800-5</td>
<td>—</td>
<td>R43 N; R51-53</td>
<td>Xi; N R: 43-51/53 S: (2-)24-37-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-296-00-6</td>
<td>A mixture of: pentaerythriol tetraesters with heptanoic acid and 2-ethylhexanoic acid</td>
<td></td>
<td>410-830-9</td>
<td>—</td>
<td>R53</td>
<td>R: 53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-297-00-1</td>
<td>(E,E)-3,3'-(1,4-phenylenedimethylidene)bis(2-oxobornane-10-sulfonic acid)</td>
<td></td>
<td>410-960-6</td>
<td>92761-26-7</td>
<td>Xi; R41</td>
<td>Xi R: 41 S: (2-)26-39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-298-00-7</td>
<td>2-(trimethylammonium)ethoxycarboxybenzene-4-sulfonate</td>
<td></td>
<td>411-010-3</td>
<td>—</td>
<td>R43</td>
<td>Xi R: 43 S: (2-)22-36/37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-299-00-2</td>
<td>methyl 3-(acetylthio)-2-methyl-propanoate</td>
<td></td>
<td>411-040-7</td>
<td>97101-46-7</td>
<td>Xn; R22 R43 N; R50-53</td>
<td>Xn; N R: 22-43-50/53 S: (2-)24-37-60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-300-00-6</td>
<td>trisodium [2-(5-chloro-2,6-difluoropyrimidin-4-ylamino)-5-(ß-sulfamoyl-c,d-sulfonatophthalocyanin-a-yl-K4,N29,N30,N31,N32-sulfonyl-lamino)benzoato[5-]cuprate] where a = 1, 2, 3, 4, b = 8, 9, 10, 11 c = 15, 16, 17, 18 d = 22, 23, 24, 25</td>
<td></td>
<td>411-430-7</td>
<td>—</td>
<td>R43</td>
<td>Xi R: 43 S: (2-)22-24-37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-301-00-1</td>
<td>A mixture of: dodecanoic acid; poly[1-7]lactate esters of dodecanoic acid</td>
<td></td>
<td>411-860-5</td>
<td>—</td>
<td>Xi; R38-41 R43 N; R51-53</td>
<td>Xi; N R: 38-41-43-51/53 S: (2-)24-26-37/39-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------</td>
<td>---------</td>
<td>----------------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>---------------------------------</td>
<td></td>
</tr>
<tr>
<td>607-302-00-7</td>
<td>A mixture of: tetradecanoic acid; poly(1-7) lactate esters of tetradecanoic acid</td>
<td>411-910-6</td>
<td>—</td>
<td>Xi; R38-41 R43 N; R51-53</td>
<td>Xi; N R: 38-41-43-51/53 S: (2-)24-26-37/39-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>607-301-00-2</td>
<td>1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid</td>
<td>413-760-7</td>
<td>93107-30-3</td>
<td>Repr. Cat.3; R62 R52-53</td>
<td>Xn R: 62-52/53 S: (2-)22-36-37/61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>608-023-00-3</td>
<td>4-(4-chlorophenyl)-2-phenyl-2-[(1H-1,2,4-triazol-1-yl)methyl]butanenitrile</td>
<td>406-140-2</td>
<td>114369-43-6</td>
<td>N; R50-53</td>
<td>N R: 50/53 S: 60-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>608-024-00-9</td>
<td>2-(4)-(N-butyl-N-phenethylamino)phenyl(ethylen-1,1,2-tricarbonitrile</td>
<td>407-650-8</td>
<td>97460-76-9</td>
<td>R53</td>
<td>R: 53 S: 61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>608-025-00-4</td>
<td>2-nitro-4,5-bis(benzyloxy)phenylacetonitrile</td>
<td>410-970-0</td>
<td>117568-27-1</td>
<td>R53</td>
<td>R: 53 S: 61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>609-053-00-X</td>
<td>hydrazine-tri-nitromethane</td>
<td>414-850-9</td>
<td>—</td>
<td>E: R3 O: R8 Carc. Cat. 2; R45 T; R23/25 R43</td>
<td>E: T R: 45-3-8-23/25-43 S: 53-45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>610-010-00-2</td>
<td>2-bromo-1-(2-furyl)-2-nitroethylene</td>
<td>406-110-9</td>
<td>35950-52-8</td>
<td>Xn; R22-48/22 C; R34 R53</td>
<td>C: N R: 22-34-43-48/22-50/53 S: (1/2-)22-26-36/37/39-45-60-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>611-043-00-5</td>
<td>A 2:1:1 mixture of: trisodium N(1''):N(2):N(1'')-N(1)-N(2')-η-6-[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxyphenylazo) -6′-(1-carbaniloyl-2-hydroxyprop-1-enzyme)-5′,5′-disulfamoyl-3,3′-disulfonatobis(naphthalene-2,1′-azobenzene-1,2′-diolato-O(1),O(2′))-chromate; trisodium N(1'')-N(2):N(1'')-N(2′)-η-6,6′-bis(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5′,5′-disulfamoyl-3,3′-disulfonatobis(naphthalene-2,1′-azobenzene-1,2′-diolato-O(1),O(2′))-chromate; trisodium N(1''):N(2):N(1′)-N(2′)-η-6,6′-bis(2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxyphenylazo)5′,5′-disulfamoyl-3,3′-disulfonatobis(naphthalene-2,1′-azobenzene-1,2′-diolato-O(1),O(2′))-chromate</td>
<td>402-850-1</td>
<td>—</td>
<td>Xi; R41 S2-53</td>
<td>Xi R: 41-52/53 S: (2-)26-39-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
</tr>
<tr>
<td>----------</td>
<td>---------------</td>
<td>-----------------------------</td>
<td>-------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>---------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>611-044-00-0</td>
<td>A mixture of: tert-alkyl(C12-C14)ammonium bis[1-[(2-hydroxy-5-nitrophenyl)azo]-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl (C12-C14)ammonium bis[1-[(2-hydroxy-4-nitrophenyl)azo]-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium bis[1-[(5-(1,1-dimethylpropyl)-2-hydroxy-3-nitrophenyl)azo]-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium-bis[1-[(2-hydroxy-5-nitrophenyl)azo]-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium-bis[1-(5-(1,1-dimethylpropyl)-2-hydroxy-3-nitrophenyl)azo]-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium(1-(4(or 5)-nitro-2-oxidophenylazo)-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium(1-(4(or 5)-nitro-2-oxidophenylazo)-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium(1-(4(or 5)-nitro-2-oxidophenylazo)-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium(1-(4(or 5)-nitro-2-oxidophenylazo)-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)ammonium(1-(4(or 5)-nitro-2-oxidophenylazo)-2-naphthalenolato(2-)]-chromate(1-); tert-alkyl(C12-C14)</td>
<td>403-720-7</td>
<td>117527-94-3</td>
<td>N: R51-53</td>
<td>N</td>
<td>R: 51/53</td>
<td>S: 61</td>
<td></td>
</tr>
<tr>
<td>611-045-00-6</td>
<td>2-[4-[N-(4-acetoxybutyl)-N-ethyl]amino-2-methylphenylazo]-3-acetyl-5-nitrothiophene</td>
<td>404-830-8</td>
<td>—</td>
<td>R53</td>
<td>R: 53</td>
<td>S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>611-046-00-1</td>
<td>4,4'-diamino-2-methylazobenzene</td>
<td>407-590-2</td>
<td>43151-99-1</td>
<td>T; R25 Xn; R48/22 R43 N; R50-53</td>
<td>T: N R: 25-43-48/22-50/53 S: (1/2)22-28-36/37-45-60-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>611-048-00-2</td>
<td>A (1:1) mixture of: 2-[[4-[bis(2-acetoxyethyl)amino]phenyl]azo]-5,6-dichlorobenzothiazole; 2-[[4-[bis(2-acetoxyethyl)amino]phenyl]azo]-6,7-dichlorobenzothiazole</td>
<td>407-900-6</td>
<td>111381-12-5</td>
<td>R53</td>
<td>R: 53</td>
<td>S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>---------------</td>
<td>-------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>--------------------------------</td>
<td></td>
</tr>
<tr>
<td>611-049-00-8</td>
<td>7-[4-(3-diethylaminopropylamino)-6-(3-diyethylaminonpropylamino)-1,3,5-triazin-2-ylamino]-4-hydroxy-3-(4-phenylazophenylazo)-naphthalene-2-sulfonate, acetic acid, lactic acid (2:1:1)</td>
<td>408-000-6</td>
<td>118658-98-3</td>
<td>Xn; R48/22 R43 R52-53</td>
<td>Xn R: 43-48/22-52/53 S: (2-22-36)/37-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>611-051-00-9</td>
<td>2-(4-[[N-methyl-N-(2-hydroxy)ethyl]amino]-2-methylphenyl]azo-6-methoxy-3-methylbenzothiazolium chloride</td>
<td>411-110-7</td>
<td>136213-74-6</td>
<td>N; R50-53</td>
<td>N R: 50/53 S: 60-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>611-052-00-4</td>
<td>monosodium aqua-[5-[[2,4-dihydroxy-3-[2-hydroxy-3,5-dinitrophenyl]azo]phenyl]azo]-2-naphthalensulfonate], iron complex</td>
<td>400-720-9</td>
<td></td>
<td></td>
<td>R: 52/53 S: 61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-158-00-3</td>
<td>A mixture of: bis(3-dodecyl-2-hydroxy benzaldoximato) copper (II) C12-alkyl group is branched; 4-dodecyl salicyldaldoxime</td>
<td>410-820-4</td>
<td></td>
<td></td>
<td></td>
<td>R: 53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>612-159-00-9</td>
<td>Reaction products of trimethylene hexamethylene diamine (a mixture of 2,2,4-trimethyl-1,6-hexanediame and 2,4,4-trimethyl-1,6-hexanediame, EINECS listed), Epoxide 8 (mono[(C10-C16-alkyl)oxy]methyl)oxiran derivatives) and p-toluene-sulfonic acid</td>
<td>410-880-1</td>
<td></td>
<td></td>
<td>X: N R: 22-34-50/53 S: (1/2)-23-26-36/37/39-45-60-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>613-149-00-7</td>
<td>2-tert-butyl-5-(4-tert-butyl benzylthio)-4-chloropyridazin-3(2H)-one</td>
<td>405-700-3</td>
<td>96489-71-3</td>
<td>T; R23/25 N: R50-53</td>
<td>T; N R: 23/25-50/53 S: (1/2)-36/37-45-60-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>613-150-00-2</td>
<td>2,2'-[3,3'-piperazine-1,4-diyl] dipropyl]bis (1H-benzimidazo[2,1-b]benzo[l,m,n][1,8]phenanthroline-1,3,6-trione</td>
<td>406-295-6</td>
<td></td>
<td></td>
<td></td>
<td>R: 53 S: 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>Notes related to substances</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>--------</td>
<td>----------------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>613-151-00-8</td>
<td>1-(3-mesyloxy-5-trityloxyethyl-2-D-threofu-ryl)thymine</td>
<td></td>
<td>406-360-9</td>
<td>104218-44-2</td>
<td>R53</td>
<td>R: 53</td>
<td>S: 61</td>
<td></td>
</tr>
<tr>
<td>613-152-00-3</td>
<td>phenyl N-(4,6-dimethoxypyrimidin-2-yl)carbamate</td>
<td></td>
<td>406-600-2</td>
<td>89392-03-0</td>
<td>R43 N; R51-53</td>
<td>Xi; N</td>
<td>R: 43-51/53 S: (2-24-37-61</td>
<td></td>
</tr>
<tr>
<td>613-153-00-9</td>
<td>2,3,5-trichloropyridine</td>
<td></td>
<td>407-270-2</td>
<td>16063-70-0</td>
<td>R52-53</td>
<td>R: 52/53</td>
<td>S: 61</td>
<td></td>
</tr>
<tr>
<td>613-154-00-4</td>
<td>2-amino-4-chloro-6-methoxypyrimidine</td>
<td></td>
<td>410-050-9</td>
<td>5734-64-5</td>
<td>Xn; R22</td>
<td>Xn</td>
<td>R: 22 S: (2-)22</td>
<td></td>
</tr>
<tr>
<td>613-155-00-X</td>
<td>5-chloro-2,3-difluoropyridine</td>
<td></td>
<td>410-090-7</td>
<td>89402-43-7</td>
<td>R10 Xi; R22 R52-53</td>
<td>Xn</td>
<td>R: 10-22-52/53 S: (2-23-36-61</td>
<td></td>
</tr>
<tr>
<td>613-156-00-5</td>
<td>2-butyl-4-chloro-5-formylimidazole</td>
<td></td>
<td>410-260-0</td>
<td>83857-96-9</td>
<td>R43 N; R51-53</td>
<td>Xi; N</td>
<td>R: 43-51/53 S: (2-24-37-61</td>
<td></td>
</tr>
<tr>
<td>613-157-00-0</td>
<td>2,4-diamino-5-methoxymethylpyrimidine</td>
<td></td>
<td>410-330-0</td>
<td>54236-98-5</td>
<td>Xn; R22-48/22 Xi; R36</td>
<td>Xn</td>
<td>R: 22-36-48/22 S: (2-)22-26-36</td>
<td></td>
</tr>
<tr>
<td>613-158-00-6</td>
<td>2,3-dichloro-5-trifluoromethyl-pyridine</td>
<td></td>
<td>410-340-5</td>
<td>69045-84-7</td>
<td>Xn; R20/22 Xi; R41 R43 N; R51-53</td>
<td>Xn; N</td>
<td>R: 20-22-41-43-51/53 S: (2-24-26-37)/39-61</td>
<td></td>
</tr>
<tr>
<td>613-159-00-1</td>
<td>4-[2-[4-[1,1-dimethylethyl]phenyl]-ethoxy]quinazoline</td>
<td></td>
<td>410-580-0</td>
<td>120928-09-8</td>
<td>T; R25 Xi; R20 R43 N; R50-53</td>
<td>T; N</td>
<td>R: 20-25-50/53 S: (1/2)-37-45-60-61</td>
<td></td>
</tr>
<tr>
<td>613-160-00-7</td>
<td>(1S)-2-methyl-2,5-diazobicyclo[2.2.1]heptane dihydrobromide</td>
<td></td>
<td>411-000-9</td>
<td>125224-62-6</td>
<td>R43</td>
<td>Xi</td>
<td>R: 43 S: (2-)24-37</td>
<td></td>
</tr>
<tr>
<td>615-022-00-1</td>
<td>methyl 3-isocyanatosulfonyl-2-thiophene-carboxylate</td>
<td></td>
<td>410-550-7</td>
<td>79277-18-2</td>
<td>E: R2 R14 Xn; R48/22 R42/43</td>
<td>E: Xn</td>
<td>R: 2-14-42/43-48/22 S: (2-)22-30-35-36/37</td>
<td></td>
</tr>
<tr>
<td>Index No</td>
<td>Chemical name</td>
<td>EC No</td>
<td>CAS No</td>
<td>Classification</td>
<td>Labelling</td>
<td>Concentration limits</td>
<td>Notes related to preparations</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------</td>
<td>--------------</td>
<td>----------------</td>
<td>-------------------</td>
<td>-------------------------------------------</td>
<td>--------------------------------</td>
<td></td>
</tr>
<tr>
<td>615-023-00-7</td>
<td>2-[(isocyanatosulfonylmethyl)benzoic acid methyl ester; (alt.): methyl 2-[(isocyanatosulfonylmethyl)benzoate]</td>
<td>410-900-9</td>
<td>83056-32-0</td>
<td>R10</td>
<td>Xn</td>
<td>R: 10-14-20-40-41-42-48/22 S: (2-)23-26-36/37/39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>616-045-00-X</td>
<td>2’-(4-chloro-3-cyano-5-formyl-2-thienylazo)-5’-diethylamino-2-methoxyacetanilide</td>
<td>405-190-2</td>
<td>122371-93-1</td>
<td>N: R50-53</td>
<td>N</td>
<td>R: 50/53 S: 60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>616-046-00-5</td>
<td>N-(2-(6-chloro-7-methylpyrazolo[1,5-b]-1,2,4-triazol-4-ylpropylo-2-(2,4-di-tert-pentylphenoxy)octanamide</td>
<td>406-390-2</td>
<td>—</td>
<td>N: R50-53</td>
<td>N</td>
<td>R: 50/53 S: 60-61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>616-047-00-0</td>
<td>A mixture of: 2, 2’ 2”, 2”-ethylenedinitrilotenakis-N,N-di(C16)alkylacetamide; 2, 2’, 2’”, 2’”-ethylenedinitrilotenakis-N,N-di(C18)alkylacetamide</td>
<td>406-640-0</td>
<td>—</td>
<td>R43</td>
<td>Xi</td>
<td>R: 43 S: (2-)24-37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>616-048-00-6</td>
<td>3’-trifluoromethylisobutylanilide</td>
<td>406-740-4</td>
<td>1939-27-1</td>
<td>Xn; R48/22 N: R51-53</td>
<td>Xn; N R: 48/22-51/53 S: (2-)22-36-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>616-049-00-1</td>
<td>2-(2,4-bis(1,1-dimethylphenoxy)-N-(3,5-dichloro-4-ethyl-2-hydroxyphenyl)-hexanamide</td>
<td>408-150-2</td>
<td>99141-89-6</td>
<td>R53</td>
<td>R: 53 S: 61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>616-050-00-7</td>
<td>N-[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoroproxy)-phenylaminocarboxyl]-2,6-difluorobenzamide</td>
<td>410-690-9</td>
<td>103055-07-8</td>
<td>R43</td>
<td>Xi; N R: 43-50/53 S: (2-)24-37-60-61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>616-051-00-2</td>
<td>A mixture of: 2,4-bis(N’-(4-methylphenyl)-ureido)-toluene; 2,6-bis(N’-(4-methylphenyl)-ureido)-toluene</td>
<td>411-070-0</td>
<td>—</td>
<td>R53</td>
<td>R: 53 S: 61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>650-032-00-X</td>
<td>cyproconazole (ISO) (2RS,3RS;2RS,3SR)-2-(4-chlorophenyl)-3-cyclopropyl-1-(1H,2,4-triazol-1-y1)butan-2-ol</td>
<td>—</td>
<td>94361-06-5</td>
<td>Repr. Cat. 3; R63 Xn; R22 N: R50-53</td>
<td>Xn; N R: 22-30/53-63 S: (2-)36/37-60-61</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ANNEX 2

R 66
IT: L'esposizione ripetuta può provocare secchezza e screpolature della pelle.

(Does not concern the ES version)
(Does not concern the DA version)
(Does not concern the DE version)
(Does not concern the EL version)
(Does not concern the EN version)
(Does not concern the FR version)
(Does not concern the NL version)
(Does not concern the PT version)
(Does not concern the FI version)
(Does not concern the SV version)
ANNEX 3A

S 23
FR: Ne pas respirer les gaz/fumées/vapeurs/aérosols [terme(s) approprié(s) à indiquer par le fabricant].

(Does not concern the ES version)
(Does not concern the DA version)
(Does not concern the DE version)
(Does not concern the EL version)
(Does not concern the EN version)
(Does not concern the IT version)
(Does not concern the NL version)
(Does not concern the PT version)
(Does not concern the FI version)
(Does not concern the SV version)

S 26
DE: Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.

(Does not concern the ES version)
(Does not concern the DA version)
(Does not concern the EL version)
(Does not concern the EN version)
(Does not concern the FR version)
(Does not concern the IT version)
(Does not concern the NL version)
(Does not concern the PT version)
(Does not concern the FI version)
(Does not concern the SV version)

S 56
DE: Diesen Stoff und seinen Behälter der Problemabfallentsorgung zuführen.
EN: Dispose of this material and its container to hazardous or special waste collection point.
IT: Smaltire questo materiale e i relativi contenitori in un punto di raccolta di rifiuti pericolosi o speciali.

(Does not concern the ES version)
(Does not concern the DA version)
(Does not concern the EL version)
(Does not concern the FR version)
(Does not concern the NL version)
(Does not concern the PT version)
(Does not concern the FI version)
(Does not concern the SV version)
ANNEX 3B

S 27/28
DE: Bei Berührung mit der Haut beschmutzte, getränkte Kleidung sofort ausziehen und Haut sofort mit viel ...
abwaschen (vom Hersteller anzugeben).

(Does not concern the ES version)
(Does not concern the DA version)
(Does not concern the EL version)
(Does not concern the EN version)
(Does not concern the FR version)
(Does not concern the IT version)
(Does not concern the NL version)
(Does not concern the PT version)
(Does not concern the FI version)
(Does not concern the SV version)

S 29/56
ES: No tirar los residuos por el desagüe; elimínese esta sustancia y su recipiente en un punto de recogida pública de ...
residuos especiales o peligrosos.

DE: Nicht in die Kanalisation gelangen lassen; diesen Stoff und seinen Behälter der Problemabfallentsorgung zuführen.

EN: Do not empty into drains, dispose of this material and its container to hazardous or special waste collection point.

IT: Non gettare i residui nelle fognature; smaltire questo materiale e i relativi contenitori in un punto di raccolta di 
ri quit pericolosi o speciali.

NL: Afval niet in de gootsteen werpen; deze stof en de verpakking naar een inzamelpunt voor gevaarlijk of bijzonder 
afval brengen.

SV: Töm ej i avloppet, lämna detta material och dess behållare till insamlingsställe för farligt avfall.

(Does not concern the DA version)
(Does not concern the EL version)
(Does not concern the FR version)
(Does not concern the PT version)
(Does not concern the FI version)
ANNEX 4A

'B.10. MUTAGENICITY — IN VITRO MAMMALIAN CHROMOSOME ABERRATION TEST

1. METHOD

This method is a replicate of the OECD TG 473, In Vitro Mammalian Chromosome Aberration Test (1997).

1.1. INTRODUCTION

The purpose of the in vitro chromosomal aberration test is to identify agents that cause structural chromosome aberrations in cultured mammalian cells (1) (2) (3). Structural aberrations may be of two types, chromosome or chromatid. With the majority of chemical mutagens, induced aberrations are of the chromatid type, but chromosome-type aberrations also occur. An increase in polyploidy may indicate that a chemical has the potential to induce numerical aberrations. However, this method is not designed to measure numerical aberrations and is not routinely used for that purpose. Chromosome mutations and related events are the cause of many human genetic diseases and there is substantial evidence that chromosome mutations and related events causing alterations in oncogenes and tumour suppressor genes of somatic cells are involved in cancer induction in humans and experimental animals.

The in vitro chromosome aberration test may employ cultures of established cells lines, cell strains or primary cell cultures. The cells used are selected on the basis of growth ability in culture, stability of the karyotype, chromosome number, chromosome diversity and spontaneous frequency of chromosome aberrations.

Tests conducted in vitro generally require the use of an exogenous source of metabolic activation. This metabolic activation system cannot mimic entirely the mammalian in vivo conditions. Care should be taken to avoid conditions which would lead to positive results which do not reflect intrinsic mutagenicity and may arise from changes in pH, osmolality or high levels of cytotoxicity (4) (5).

This test is used to screen for possible mammalian mutagens and carcinogens. Many compounds that are positive in this test are mammalian carcinogens; however, there is not a perfect correlation between this test and carcinogenicity. Correlation is dependent on chemical class and there is increasing evidence that there are carcinogens that are not detected by this test because they appear to act through mechanisms other than direct DNA damage.

See also General Introduction Part B.

1.2. DEFINITIONS

Chromatid-type aberration: structural chromosome damage expressed as breakage of single chromatids or breakage and reunion between chromatids.

Chromatid-type aberration: structural chromosome damage expressed as breakage, or breakage and reunion, of both chromatids at an identical site.

Endoreduplication: a process in which after an S period of DNA replication, the nucleus does not go into mitosis but starts another S period. The result is chromosomes with 4, 8, 16, … chromatids.

Gap: an achromatic lesion smaller than the width of one chromatid, and with minimum misalignment of the chromatids.

Mitotic index: the ratio of cells in metaphase divided by the total number of cells observed in a population of cells; an indication of the degree of proliferation of that population.

Numerical aberration: a change in the number of chromosomes from the normal number characteristic of the cells utilised.
**Polyploidy:** a multiple of the haploid chromosome number (n) other than the diploid number (i.e. 3n, 4n, and so on).

**Structural aberration:** a change in chromosome structure detectable by microscopic examination of the metaphase stage of cell division, observed as deletions and fragments, intrachanges or interchanges.

1.3. PRINCIPLE OF THE TEST METHOD

Cell cultures are exposed to the test substance both with and without metabolic activation. At predetermined intervals after exposure of cell cultures to the test substance, they are treated with a metaphase arresting substance (e.g. Colcemid® or colchicine), harvested, stained and metaphase cells are analysed microscopically for the presence of chromosome aberrations.

1.4. DESCRIPTION OF THE TEST METHOD

1.4.1. Preparations

1.4.1.1. Cells

A variety of cell lines, strains or primary cell cultures, including human cells, may be used (e.g. Chinese hamster fibroblasts, human or other mammalian peripheral blood lymphocytes).

1.4.1.2. Media and culture conditions

Appropriate culture media, and incubation conditions (culture vessels, CO₂ concentration, temperature and humidity) should be used in maintaining cultures. Established cell lines and strains should be checked routinely for stability in the modal chromosome number and the absence of mycoplasma contamination and should not be used if contaminated. The normal cell cycle time for the cells and culture conditions used should be known.

1.4.1.3. Preparation of cultures

Established cell lines and strains: cells are propagated from stock cultures, seeded in culture medium at a density such that the cultures will not reach confluency before the time of harvest, and incubated at 37°C.

Lymphocytes: whole blood treated with an anti-coagulant (e.g. heparin) or separated lymphocytes obtained from healthy subjects are added to the culture medium containing a mitogen (e.g. phytohaemagglutinin) and incubated at 37°C.

1.4.1.4. Metabolic activation

Cells should be exposed to the test substance both in the presence and absence of an appropriate metabolic activation system. The most commonly used system is a cofactor-supplemented post-mitochondrial fraction (S9) prepared from the livers of rodents treated with enzyme-inducing agents such as Aroclor 1254 (6) (7) (8) (9), or a mixture of phenobarbitone and β-naphthoflavone (10) (11) (12).

The post-mitochondrial fraction is usually used at concentrations in the range from 1—10% v/v in the final test medium. The condition of a metabolic activation system may depend upon the class of chemical being tested. In some cases it may be appropriate to utilise more than one concentration of post-mitochondrial fraction.

A number of developments, including the construction of genetically engineered cell lines expressing specific activating enzymes, may provide the potential for endogenous activation. The choice of the cell lines used should be scientifically justified (e.g. by the relevance of the cytochrome P450 isoenzyme for the metabolism of the test substance).
1.4.1.5. Test substance/Preparation

Solid test substances should be dissolved or suspended in appropriate solvents or vehicles and diluted if appropriate prior to treatment of the cells. Liquid test substances may be added directly to the test systems and/or diluted prior to treatment. Fresh preparations of the test substance should be employed unless stability data demonstrate the acceptability of storage.

1.4.2. Test conditions

1.4.2.1. Solvent/vehicle

The solvent/vehicle should not be suspected of chemical reaction with the test substance and should be compatible with the survival of the cells and the S9 activity. If other than well-known solvent/vehicles are used, their inclusion should be supported by data indicating their compatibility. It is recommended that wherever possible, the use of an aqueous solvent/vehicle be considered first. When testing water-unstable substances, the organic solvents used should be free of water. Water can be removed by adding a molecular sieve.

1.4.2.2. Exposure concentrations

Among the criteria to be considered when determining the highest concentration are cytotoxicity, solubility in the test system and changes in pH or osmolality.

Cytotoxicity should be determined with and without metabolic activation in the main experiment using an appropriate indication of cell integrity and growth, such as degree of confluency, viable cell counts, or mitotic index. It may be useful to determine cytotoxicity and solubility in a preliminary experiment.

At least three analysable concentrations should be used. Where cytotoxicity occurs, these concentrations should cover a range from the maximum to little or no toxicity; this will usually mean the concentrations should be separated by no more than a factor between 2 and $\sqrt{10}$. At the time of harvesting, the highest concentration should show a significant reduction in degree of confluency, cell count or mitotic index (all greater than 50%). The mitotic index is only an indirect measure of cytotoxic/cytostatic effects and depends on the time after treatment. However, the mitotic index is acceptable for suspension cultures in which other toxicity measurements may be cumbersome and impractical. Information on cell cycle kinetics, such as average generation time (AGT), could be used as supplementary information AGT, however, is an overall average that does not always reveal the existence of delayed subpopulations, and even slight increases in average generation time can be associated with very substantial delay in the time of optimal yield of aberrations.

For relatively non-cytotoxic substances, the maximum test concentration should be 5µl/ml, 5 mg/ml or 0,01 M, whichever is the lowest.

For relatively insoluble substances that are not toxic at concentrations lower than the insoluble concentration, the highest dose used should be a concentration above the limit of solubility in the final culture medium at the end of the treatment period. In some cases (e.g. when toxicity occurs only at higher than the lowest insoluble concentration), it is advisable to test at more than one concentration with visible precipitation. It may be useful to assess solubility at the beginning and the end of the treatment, as solubility can change during the course of exposure in the test system due to presence of cells, S9 serum, etc. Insolubility can be detected by using the unaided eye. The precipitate should not interfere with the scoring.

1.4.2.3. Negative and positive controls

Concurrent positive and negative (solvent or vehicle) controls, both with and without metabolic activation, should be included in each experiment. When metabolic activation is used, the positive control chemical should be the one that requires activation to give a mutagenic response.

Positive controls should employ a known elastogen at exposure levels expected to give a reproducible and detectable increase over background which demonstrates the sensitivity of the test system.
Positive control concentrations should be chosen so that the effects are clear but do not immediately reveal the identity of the coded slides to the reader. Examples of positive control substances include:

<table>
<thead>
<tr>
<th>Metabolic activation condition</th>
<th>Substance</th>
<th>CAS No</th>
<th>Einecs No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absence of exogenous metabolic activation</td>
<td>methyl methanesulphonate</td>
<td>66-27-3</td>
<td>200-625-0</td>
</tr>
<tr>
<td></td>
<td>ethyl methanesulphonate</td>
<td>62-50-0</td>
<td>200-536-7</td>
</tr>
<tr>
<td></td>
<td>ethyl nitrosourea</td>
<td>759-73-9</td>
<td>212-072-2</td>
</tr>
<tr>
<td></td>
<td>mitomycin C</td>
<td>50-07-7</td>
<td>200-008-6</td>
</tr>
<tr>
<td></td>
<td>4-nitroquinoline-N-oxide</td>
<td>56-57-5</td>
<td>200-281-1</td>
</tr>
<tr>
<td>Presence of exogenous metabolic activation</td>
<td>benzo[a]pyrene</td>
<td>50-32-8</td>
<td>200-028-5</td>
</tr>
<tr>
<td></td>
<td>cyclophosphamide</td>
<td>50-18-0</td>
<td>200-015-4</td>
</tr>
<tr>
<td></td>
<td>cyclophosphamide monohydrate</td>
<td>6055-19-2</td>
<td></td>
</tr>
</tbody>
</table>

Other appropriate positive control substances may be used. The use of chemical class-related positive control chemicals should be considered, when available.

Negative controls, consisting of solvent or vehicle alone in the treatment medium, and treated in the same way as the treatment cultures, should be included for every harvest time. In addition, untreated controls should also be used unless there are historical control data demonstrating that no deleterious or mutagenic effects are induced by the chosen solvent.

1.4.3. **Procedure**

1.4.3.1. **Treatment with the test substance**

Proliferating cells are treated with the test substance in the presence and absence of a metabolic activation system. Treatment of lymphocytes should commence at about 48 hours after mitogenic stimulation.

1.4.3.2. Duplicate cultures should normally be used at each concentration, and are strongly recommended for negative/solvent control cultures. Where minimal variation between duplicate cultures can be demonstrated (13) (14), from historical data, it may be acceptable for single cultures to be used at each concentration.

Gaseous or volatile substances should be tested by appropriate methods, such as in sealed culture vessels (15) (16).

1.4.3.3. **Culture harvest time**

In the first experiment, cells should be exposed to the test substance, both with and without metabolic activation, for 3—6 hours, and sampled at a time equivalent to about 1.5 normal cell cycle length after the beginning of treatment (12). If this protocol gives negative results both with and without activation, an additional experiment without activation should be done, with continuous treatment until sampling at a time equivalent to about 1.5 normal cell cycle lengths. Certain chemicals may be more readily detected by treatment/sampling times longer than 1.5 cycle lengths. Negative results with metabolic activation need to be conformed on a case-by-case basis. In those cases where confirmation of negative results is not considered necessary, justification should be provided.
1.4.3.4. Chromosome preparation

Cell cultures are treated with Colcemid® or colchicine usually for 1—3 hours prior to harvesting. Each cell culture is harvested and processed separately for the preparation of chromosomes. Chromosome preparation involves hypotonic treatment of the cells, fixation and staining.

1.4.3.5. Analysis

All slides, including those of positive and negative controls, should be independently coded before microscopic analysis. Since fixation procedures often result in the breakage of a proportion of metaphase cells with loss of chromosomes, the cells scored should therefore contain a number of centromeres equal to the modal number ±2 for all cell types. At least 200 well-spread metaphases should be scored per concentration and control, equally divided amongst the duplicates, if applicable. This number can be reduced when a high number of aberrations is observed.

Though the purpose of the test is to detect structural chromosome aberrations, it is important to record polyploidy and endoreduplication when these events are seen.

2. DATA

2.1. Treatment of results

The experimental unit is the cell, and therefore the percentage of cells with structural chromosome aberration(s) should be evaluated. Different types of structural chromosome aberrations should be listed with their numbers and frequencies for experimental and control cultures. Gaps are recorded separately and reported but generally not included in the total aberration frequency.

Concurrent measures of cytotoxicity for all treated and negative control cultures in the main aberration experiments should also be recorded.

Individual culture data should be provided. Additionally, all data should be summarised in tabular form.

There is no requirement for verification of a clear positive response. Equivocal results should be clarified by further testing preferably using modification of experimental conditions. The need to confirm negative results has been discussed in 1.4.3.3. Modification of study parameters to extend the range of conditions assessed should be considered in follow-up experiments. Study parameters that might be modified include the concentration spacing and the metabolic activation conditions.

2.2. Evaluation and interpretation of results

There are several criteria for determining a positive result, such as a concentration-related increase or a reproducible increase in the number of cells with chromosome aberrations. Biological relevance of the results should be considered first. Statistical methods may be used as an aid in evaluating the test results (3) (13). Statistical significance should not be the only determining factor for a positive response.

An increase in the number of polyploid cells may indicate that the test substance has the potential to inhibit mitotic processes and to induce numerical chromosome aberrations. An increase in the number of cells with endoreduplicated chromosomes may indicate that the test substance has the potential to inhibit cell cycle progression (17) (18).

A test substance for which the results do not meet the above criteria is considered non-mutagenic in this system.

Although most experiments will give clearly positive or negative results, in rare cases the data set will preclude making a definite judgement about the activity of the test substance. Results may remain equivocal or questionable regardless of the number of times the experiment is repeated.
Positive results from the *in vitro* chromosome aberration test indicate that the test substance induces structural chromosome aberrations in cultured mammalian somatic cells. Negative results indicate that, under the test conditions, the test substance does not induce chromosome aberrations in cultured mammalian somatic cells.

3. REPORTING

TEST REPORT

The test report must include the following information:

Solvent/vehicle:

— justification for choice of vehicle,
— solubility and stability of the test substance in solvent/vehicle, if known.

Cells:

— type and source of cells,
— karyotype features and suitability of the cell type used,
— absence of mycoplasma, if applicable,
— information on cell cycle length,
— sex of blood donors, whole blood or separated lymphocytes, mitogen used,
— number of passages, if applicable,
— methods for maintenance of cell culture, if applicable,
— modal number of chromosomes.

Test conditions:

— identity of metaphase arresting substance, its concentration and duration of cell exposure,
— rationale for selection of concentrations and number of cultures including, e.g. cytotoxicity data and solubility limitations, if available,
— composition of media, CO₂ concentration if applicable,
— concentration of test substance,
— volume of vehicle and test substance added,
— incubation temperature,
— incubation time,
— duration of treatment,
— cell density at seeding, if appropriate,
— type and composition of metabolic activation system, including acceptability criteria,
— positive and negative controls,
— methods of slide preparation,
— criteria for scoring aberrations,
— number of metaphases analysed,
— methods for the measurements of toxicity,
— criteria for considering studies as positive, negative or equivocal,

Results:
— signs of toxicity, e.g. degree of confluency, cell cycle data, cell counts, mitotic index,
— signs of precipitation,
— data on pH and osmolality of the treatment medium, if determined,
— definition for aberrations, including gaps,
— number of cells with chromosome aberrations and type of chromosome aberrations given separately for each treated and control culture,
— changes in ploidy if seen,
— dose-response relationship, where possible,
— statistical analyses, if any,
— concurrent negative (solvent/vehicle) and positive control data,
— historical negative (solvent/vehicle) and positive control data, with ranges, means and standard deviations.

Discussion of results.

Conclusions.

4. REFERENCES


ANNEX 4B

'B.11. MUTAGENICITY — IN VIVO MAMMALIAN BONE MARROW CHROMOSOME ABERRATION TEST

1. METHOD

This method is a replicate of the OECD TG 475, Mammalian Bone Marrow Chromosome Aberration Test (1997).

1.1. INTRODUCTION

The mammalian in vivo chromosome aberration test is used for the detection of structural chromosome aberrations induced by the test substance to the bone marrow cells of animals, usually rodents (1) (2) (3) (4). Structural chromosome aberrations may be of two types, chromosome or chromatid. An increase in polyploidy may indicate that a chemical has the potential to induce numerical aberrations. With the majority of chemical mutagens, induced aberrations are of the chromatid-type, but chromosome-type aberrations also occur. Chromosome mutations and related events are the cause of human genetic diseases and there is substantial evidence that chromosome mutations and related events causing alterations in oncogenes and tumour suppressor genes are involved in cancer in humans and experimental systems.

Rodents are routinely used in this test. Bone marrow is the target tissue in this test, since it is a highly vascularised tissue, and it contains a population of rapidly cycling cells that can be readily isolated and processed. Other species and target tissues are not the subject of this method.

This chromosome aberration test is especially relevant to assessing mutagenic hazard in that it allows consideration of factors of in vivo metabolism, pharmacokinetics and DNA-repair processes although these may vary among species and among tissues. An in vivo test is also useful for further investigation of a mutagenic effect detected by an in vitro test.

If there is evidence that the test substance, or a reactive metabolite, will not reach the target tissue, it is not appropriate to use this test.

See also General introduction Part B.

1.2. DEFINITIONS

Chromatid-type aberration: structural chromosome damage expressed as breakage of single chromatids or breakage and reunion between chromatids.

Chromosome-type aberration: structural chromosome damage expressed as breakage, or breakage and reunion, of both chromatids at an identical site.

Endoreduplication: a process in which after an S period of DNA replication, the nucleus does not go into mitosis but starts another S period. The result is chromosomes with 4, 8, 16, ... chromatids.

Gap: an achromatic lesion smaller than the width of one chromatid, and with minimum misalignment of the chromatid(s).

Numerical aberration: a change in the number of chromosomes from the normal number characteristic of the cells utilised.

Polyploidy: a multiple of the haploid chromosome number (n) other than the diploid number (i.e. 3n, 4n and so on).

Structural aberration: a change in chromosome structure detectable by microscopic examination of the metaphase stage of cell division, observed as deletions and fragments, intrachanges or interchanges.
1.3. PRINCIPLE OF THE TEST METHOD

Animals are exposed to the test substance by an appropriate route of exposure and are sacrificed at appropriate times after treatment. Prior to sacrifice, animals are treated with a metaphase arresting agent (e.g. colchicine or Colcemid®). Chromosome preparations are then made from the bone marrow cells and stained, and metaphase cells are analysed for chromosome aberrations.

1.4. DESCRIPTION OF THE TEST METHOD

1.4.1. Preparations

1.4.1.1. Selection of animals species

Rats, mice and Chinese hamsters are commonly used, although any appropriate mammalian species may be used. Commonly used laboratory strains of young healthy adult animals should be employed. At the commencement of the study, the weight variation of animals should be minimal and not exceed ± 20% of the mean weight of each sex.

1.4.1.2. Housing and feeding conditions

General conditions referred in the General Introduction to Part B are applied although the aim for humidity should be 50–60%.

1.4.1.3. Preparation of the animals

Healthy young adult animals are randomly assigned to the control and treatment groups. Cages should be arranged in such a way that possible effects due to cage placement are minimised. The animals are identified uniquely. The animals are acclimated to the laboratory conditions for at least five days.

1.4.1.4. Preparation of doses

Solid test substances should be dissolved or suspended in appropriate solvents or vehicles and diluted, if appropriate, prior to dosing of the animals. Liquid test substances may be dosed directly or diluted prior to dosing. Fresh preparations of the test substance should be employed unless stability data demonstrate the acceptability of storage.

1.4.2. Test conditions

1.4.2.1. Solvent/vehicle

The solvent/vehicle should not produce toxic effects at the dose levels used, and should not be suspected of chemical reaction with the test substance. If other than well-known solvents/vehicles are used, their inclusion should be supported with data indicating their compatibility. It is recommended that wherever possible, the use of an aqueous solvent/vehicle should be considered first.

1.4.2.2. Controls

Concurrent positive and negative (solvent/vehicle) controls should be included for each sex in each test. Except for treatment with the test substance, animals in the control groups should be handled in an identical manner to the animals in the treated groups.

Positive controls should produce structural aberrations in vivo at exposure levels expected to give a detectable increase over background. Positive control doses should be chosen so that the effects are clear but do not immediately reveal the identity of the coded slides to the reader. It is acceptable that the positive control be
administered by a route different from the test substance and sampled at only a single time. The use of chemical class related positive control chemicals may be considered, when available. Examples of positive control substances include:

<table>
<thead>
<tr>
<th>Substance</th>
<th>CAS No</th>
<th>EINECS No</th>
</tr>
</thead>
<tbody>
<tr>
<td>ethyl methansulphonate</td>
<td>62-50-0</td>
<td>200-536-7</td>
</tr>
<tr>
<td>ethyl nitrosourea</td>
<td>759-73-9</td>
<td>212-072-2</td>
</tr>
<tr>
<td>mitomycin C</td>
<td>50-07-7</td>
<td>200-008-6</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>50-18-0</td>
<td>200-015-4</td>
</tr>
<tr>
<td>cyclophosphamide monohydrate</td>
<td>6055-19-2</td>
<td></td>
</tr>
<tr>
<td>triethylenemelamine</td>
<td>51–18–3</td>
<td>200-083-5</td>
</tr>
</tbody>
</table>

Negative controls, treated with solvent or vehicle alone, and otherwise treated in the same way as the treatment groups, should be included for every sampling time, unless acceptable inter-animal variability and frequencies of cells with chromosome aberrations are available from historical control data. If single sampling is applied for negative controls, the most appropriate time is the first sampling time. In addition, untreated controls should also be used unless there are historical or published control data demonstrating that no deleterious or mutagenic effects are induced by the chosen solvent/vehicle.

1.5. PROCEDURE

1.5.1. Number and sex of animals

Each treated and control group include at least five analysable animals per sex. If at the time of the study there are data available from studies in the same species and using the same route of exposure that demonstrate that there are no substantial differences in toxicity between sexes, then testing in a single sex will be sufficient. Where human exposure to chemicals may be sex-specific, as for example with some pharmaceutical agents, the test should be performed with animals of the appropriate sex.

1.5.2. Treatment schedule

Test substances are preferably administered as a single treatment. Test substances may also be administered as a split dose, i.e. two treatments on the same day separated by no more than a few hours, to facilitate administering a large volume of material. Other dose regimens should be scientifically justified.

Samples should be taken at two separate times following treatment on one day. For rodents, the first sampling interval is 1.5 normal cell cycle length (the latter being normally 12–18 hours) following treatment. Since the time required for uptake and metabolism of the test substance as well as its effect on cell cycle kinetics can affect the optimum time for chromosome aberration detection, a later sample collection 24 hours after the first sample time is recommended. If dose regimens of more than one day are used, one sampling time at 1.5 normal cell cycle lengths after the final treatment should be used.

Prior to sacrifice, animals are injected intraperitoneally with an appropriate dose of a metaphase arresting agent (e.g. Colcemid® or colchicine). Animals are sampled at an appropriate interval thereafter. For mice this interval is approximately 3–5 hours; for Chinese hamsters this interval as approximately 4–5 hours. Cells are harvested from the bone marrow and analysed for chromosome aberrations.
1.5.3. Dose levels

If a range finding study is performed because there are no suitable data available, it should be performed in the same laboratory, using the same species, strain, sex, and treatment regimen to be used in the main study (5). If there is toxicity, three dose levels are used for the first sampling time. These dose levels should cover a range from the maximum to little or no toxicity. At the later sampling time only the highest dose needs to be used. The highest dose is defined as the dose-producing signs of toxicity such that higher dose levels, based on the same dosing regimen, would be expected to produce lethality. Substances with specific biological activities at low non-toxic doses (such as hormones and mitogens) may be exceptions to the dose-setting criteria and should be evaluated on a case-by-case basis. The highest dose may also be defined as a dose that produces some indication of toxicity in the bone marrow (e.g. greater than 50% reduction in mitotic index).

1.5.4. Limit test

If a test at one dose level of at least 2 000 mg/kg body weight using a single treatment, or as two treatments on the same day, produces no observable toxic effects, and if genotoxicity would not be expected based on data from structurally related substances, then a fully study using three dose levels may not be considered necessary. For studies of a longer duration, the limit dose is 2 000 mg/kg body weight/day for treatment up to 14 days, and 1 000 mg/kg body weight/day for treatment longer than 14 days. Expected human exposure may indicate the need for a higher dose level to be used in the limit test.

1.5.5. Administration of doses

The test substance is usually administered by gavage using a stomach tube or a suitable intubation cannula, or by intraperitoneal injection. Other routes of exposure may be acceptable where they can be justified. The maximum volume of liquid that can be administered by gavage or injection at one time depends on the size of the test animal. The volume should not exceed 2 ml/100g body weight. The use of volumes higher than these must be justified. Except for irritating or corrosive substances which will normally reveal exacerbated effects with higher concentrations, variability in test volume should be minimised by adjusting the concentration to ensure a constant volume at all dose levels.

1.5.6. Chromosome preparation

Immediately after sacrifice, bone marrow is obtained, exposed to hypotonic solution and fixed. The cells are then spread on slides and stained.

1.5.7. Analysis

The mitotic index should be determined as a measure of cytotoxicity in at least 1 000 cells per animal for all treated animals (including positive controls) and untreated negative control animals.

At least 100 cells should be analysed for each animal. This number could be reduced when high numbers of aberrations are observed. All slides, including those of positive and negative controls, should be independently coded before microscopic analysis. Since slide preparation procedures often result in the breakage of a proportion of metaphases with loss of chromosomes, the cells scored should therefore contain a number of centromeres equal to the number \( 2n \pm 2 \).

2. DATA

2.1. Treatment of results

Individual animal data should be presented in tabular form. The experimental unit is the animal. For each animal the number of cells scored, the number of aberrations per cell and the percentage of cells with structural chromosome aberration(s) should be evaluated. Different types of structural chromosome aberrations should be listed with their numbers and frequencies for treated and control groups. Gaps are recorded separately and reported but generally not included in the total aberration frequency. If there is no evidence for a difference in response between the sexes, the data from both sexes may be combined for statistical analysis.
2.2. EVALUATION AND INTERPRETATION OF RESULTS

There are several criteria for determining a positive result, such as a dose-related increase in the relative number of cells with chromosome aberrations or a clear increase in the number of cells with aberrations in a single dose group at a single sampling time. Biological relevance of the results should be considered first. Statistical methods may be used as an aid in evaluating the test results (6). Statistical significance should not be the only determining factor for a positive response. Equivocal results should be clarified by further testing preferably using a modification of experimental conditions.

An increase in polyploidy may indicate that the test substance has the potential to induce numerical chromosome aberrations. An increase in endoreduplication may indicate that the test substance has the potential to inhibit cell cycle progression (7) (8).

A test substance for which the results do not meet the above criteria is considered non-mutagenic in this test.

Although most experiments will give clearly positive or negative results, in rare cases the data set will preclude making a definite judgement about the activity of the test substance. Results may remain equivocal or questionable regardless of the number of experiments performed.

Positive results from the in vivo chromosome aberration test indicate that a substance induces chromosome aberrations in the bone marrow of the species tested. Negative results indicate that, under the test conditions, the test substance does not induce chromosome aberrations in the bone marrow of the species tested.

The likelihood that the test substance or its metabolites reach the general circulation or specifically the target tissue (e.g. systemic toxicity) should be discussed.

3. REPORTING

TEST REPORT

Test test report must include the following information:

Solvent vehicle:
— justification for choice of vehicle,
— solubility and stability of the test substance in solvent/vehicle, if known.

Test animals:
— species/strain used,
— number, age and sex of animals,
— source, housing conditions, diet, etc.,
— individual weight of the animals at the start of the test, including body weight range, means and standard deviation for each group.

Test conditions:
— positive and negative (vehicle/solvent) controls,
— data from range-finding study, if conducted,
— rationale for close level selection,
— details of test substance preparation,
— details of the administration of the test substance,
— rationale for route of administration,
— methods for verifying that the test substance reached the general circulation or target tissue, if applicable,
— conversion from diet/drinking water test substance concentration (ppm) to the actual dose (mg/kg body weight/day), if applicable,
— details of food and water quality,
— detailed description of treatment and sampling schedules,
— methods for measurements of toxicity,
— identity of metaphase arresting substance, its concentration and duration of treatment,
— methods of slide preparation,
— criteria for scoring aberrations,
— number of cells analysed per animal,
— criteria for considering studies as positive, negative or equivocal.

Results:
— signs of toxicity,
— mitotic index,
— type and number of aberrations, given separately for each animal,
— total number of aberrations per group with means and standard deviations,
— number of cells with aberrations per group with means and standard deviations,
— changes in ploidy, if seen,
— dose-response relationship, where possible,
— statistical analyses, if any,
— concurrent negative control data,
— historical negative control data with ranges, means and standard deviations,
— concurrent positive control data.

Discussion of the results.

Conclusions.

4. REFERENCES


ANNEX 4C

‘B.12. MUTAGENICITY — IN VIVO MAMMALIAN ERYTHROCYTE MICRONUCLEUS TEST

1. METHOD

This method is a replicate of the OECD TG 474, Mammalian Erythrocyte Micronucleus Test (1997).

1.1. INTRODUCTION

The mammalian in vivo micronucleus test is used for the detection of damage induced by the test substance to the chromosomes or the mitotic apparatus of erythroblasts by analysis of erythrocytes as sampled in bone marrow and/or peripheral blood cells of animals, usually rodents.

The purpose of the micronucleus test is to identify substances that cause cytogenetic damage which results in the formation of micronuclei containing lagging chromosome fragments or whole chromosomes.

When a bone marrow erythroblast develops into a polychromatic erythrocyte, the main nucleus is extruded; any micronucleus that has been formed may remain behind in the otherwise anucleated cytoplasm. Visualisation of micronuclei is facilitated in these cells because they lack a main nucleus. An increase in the frequency of micronucleated polychromatic erythrocytes in treated animals is an indication of induced chromosome damage.

The bone marrow of rodents is routinely used in this test since polychromatic erythrocytes are produced in that tissue. The measurement of micronucleated immature (polychromatic) erythrocytes in peripheral blood is equally acceptable in any species in which the inability of the spleen to remove micronucleated erythrocytes has been demonstrated, or which has shown an adequate sensitivity to detect agents that cause structural or numerical chromosome aberrations. Micronuclei can be distinguished by a number of criteria. These include identification of the presence or absence of a kinetochore or centromeric DNA in the micronuclei. The frequency of micronucleated immature (polychromatic) erythrocytes is the principal end point. The number of mature (normochromatic) erythrocytes in the peripheral blood that contain micronuclei among a given number of mature erythrocytes can also be used as the endpoint of the assay when animals are treated for four weeks or more.

This mammalian in vivo micronucleus test especially relevant to assessing mutagenic hazard in that it allows consideration of factors of in vivo metabolism, pharmacokinetics and DNA repair processes although these may vary among species, among tissues and among genetic endpoints. An in vivo assay is also useful for further investigation of a mutagenic effect detected by an in vitro system.

If there is evidence that the test substance, or a reactive metabolite, will not reach the target tissue, it is not appropriate to use this test.

See also General Introduction Part B.

1.2. DEFINITIONS

Centromere (Kinetochore): region(s) of a chromosome with which spindle fibers are associated during cell division, allowing orderly movement of daughter chromosomes to the poles of the daughter cells.

Micronuclei: small nuclei, separate from and additional to the main nuclei of cells, produced during telophase of mitosis (meiosis) by lagging chromosome fragments or whole chromosomes.

Normochromic erythrocyte: mature erythrocyte that lacks ribosomes and can be distinguished from immature, polychromatic erythrocytes by stains selective for ribosomes.
Polychromatic erythrocyte: immature erythrocyte, in an intermediate stage of development, that still contains ribosomes and therefore can be distinguished from mature, normochromatic erythrocytes by stains selective for ribosomes.

1.3. PRINCIPLE OF THE TEST METHOD

Animals are exposed to the test substance by an appropriate route. If bone marrow is used, the animals are sacrificed at appropriate times after treatment, the bone marrow extracted, and preparations made and stained (1) (2) (3) (4) (5) (6) (7). When peripheral blood is used, the blood is collected at appropriate times after treatment and smear preparations are made and stained (4) (8) (9) (10). For studies with peripheral blood, as little time as possible should elapse between the last exposure and cell harvest. Preparations are analysed for the presence of micronuclei.

1.4. DESCRIPTION OF THE TEST METHOD

1.4.1. Preparations

1.4.1.1. Selection of animal species

Mice or rats are recommended if bone marrow is used, although any appropriate mammalian species may be used. When peripheral blood is used, mice are recommended. However, any appropriate mammalian species may be used provided it is a species in which the spleen does not remove micronucleated erythrocytes or a species which has shown an adequate sensitivity to detect agents that cause structural or numerical chromosome aberrations. Commonly used laboratory strains of young healthy animals should be employed. At the commencement of the study, the weight variation of animals should be minimal and not exceed ± 20% of the mean weight of each sex.

1.4.1.2. Housing and feeding conditions

General conditions referred in the General Introduction to Part B are applied although the aim for humidity should be 50–60%.

1.4.1.3. Preparation of the animals

Healthy young adult animals are randomly assigned to the control and treatment groups. The animals are identified uniquely. The animals are acclimated to the laboratory conditions for at least five days. Cages should be arranged in such a way that possible effects due to cage placement are minimised.

1.4.1.4. Preparation of doses

Solid test substances should be dissolved or suspended in appropriate solvents or vehicles and diluted, if appropriate, prior to dosing of the animals. Liquid test substances may be dosed directly or diluted prior to dosing. Fresh preparations of the test substance should be employed unless stability data demonstrate the acceptability of storage.

1.4.2. Test conditions

1.4.2.1. Solvent/vehicle

The solvent/vehicle should not produce toxic effects at the dose levels used, and should not be suspected of chemical reaction with the test substance. If other than well-known solvents/vehicles are used, their inclusion should be supported with reference data indicating their compatibility. It is recommended that wherever possible, the use of aqueous solvent/vehicle should be considered first.

1.4.2.2. Controls

Concurrent positive and negative (solvent/vehicle) controls should be included for each sex in each test. Except for treatment with the test substance, animals in the control groups should be handled in an identical manner to animals of the treatment groups.
Positive controls should produce micronuclei in vivo at exposure levels expected to give a detectable increase over background. Positive control doses should be chosen so that the effects are clear but do not immediately reveal the identity of the coded slides to the reader. It is acceptable that the positive control be administered by a route different from the test substance and sampled at only a single time. In addition, the use of chemical class-related positive control chemicals may be considered, when available. Examples of positive control substances include:

<table>
<thead>
<tr>
<th>Substance</th>
<th>CAS No</th>
<th>Eines No</th>
</tr>
</thead>
<tbody>
<tr>
<td>ethyl methansulphonate</td>
<td>62-50-0</td>
<td>200-536-7</td>
</tr>
<tr>
<td>N-ethyl-N-nitrosourea</td>
<td>759-73-9</td>
<td>212-072-2</td>
</tr>
<tr>
<td>mitomycin C</td>
<td>50-07-7</td>
<td>200-008-6</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>50-18-0</td>
<td>200-015-4</td>
</tr>
<tr>
<td>cyclophosphamide monohydrate</td>
<td>6055-19-2</td>
<td></td>
</tr>
<tr>
<td>triethylenemelamine</td>
<td>51–18–3</td>
<td>200-083-5</td>
</tr>
</tbody>
</table>

Negative controls, treated with solvent or vehicle alone, and otherwise treated in the same way as the treatment groups should be included for every sampling time, unless acceptable inter-animal variability and frequencies of cells with micronuclei are demonstrated by historical control data. If single sampling is applied for negative controls, the most appropriate time is the first sampling time. In addition, untreated controls should also be used unless there are historical or published control data demonstrating that no deleterious or mutagenic effects are induced by the chosen solvent/vehicle.

If peripheral blood is used, a pre-treatment sample may also be acceptable as a concurrent negative control, but only in the short peripheral blood studies (e.g. 1–3 treatment(s)) when the resulting data are in the expected range for the historical control.

1.5. PROCEDURE

1.5.1. Number and sex of animals

Each treated and control group must include at least five analysable animals per sex (11). If at the time of the study there are data available from studies in the same species and using the same route of exposure that demonstrate that there are no substantial differences between sexes in toxicity, then testing in a single sex will be sufficient. Where human exposure to chemicals may be sex-specific, as for example with some pharmaceutical agents, the test should be performed with animals of the appropriate sex.

1.5.2. Treatment schedule

No standard treatment schedule (i.e. one, two or more treatments at 24-hour intervals) can be recommended. The samples from extended dose regimens are acceptable as long as a positive effect has been demonstrated for this study or, for a negative study, as long as toxicity has been demonstrated or the limit dose has been used, and dosing continued until the time of sampling. Test substances may also be administered as a split dose, i.e. two treatments on the same day separated by no more than a few hours, to facilitate administering a large volume of material.

The test may be performed in two ways:

(a) animals are treated with the test substance once. Samples of bone marrow are taken at least twice, starting not earlier than 24 hours after treatment, but not extending beyond 48 hours after treatment with appropriate intervals between samples. The use of sampling times earlier than 24 hours after treatment should be justified. Samples of peripheral blood are taken at least twice, starting not earlier
than 36 hours after treatment, with appropriate intervals following the first sample, but not extending beyond 72 hours. When a positive response is recognised at one sampling time, additional sampling is not required.

(b) If two or more daily treatments are used (e.g. two or more treatments at 24-hour intervals), samples should be collected once between 18 and 24 hours following the final treatment for the bone marrow and once between 36 and 48 hours following the final treatment for the peripheral blood (12).

Other sampling times may be used in addition, when relevant.

1.5.3. Dose levels

If a range finding study is performed because there are not suitable data available, it should be performed in the same laboratory, using the same species, strain, sex, and treatment regimen to be used in the main study (13). If there is toxicity, three dose levels are used for the first sampling time. These dose levels should cover a range from the maximum to little or no toxicity. At the later sampling time only the highest dose needs to be used. The highest dose is defined as the dose producing signs of toxicity such that higher dose levels, based on the same dosing regimen, would be expected to produce lethality. Substances with specific biological activities at low non-toxic doses (such as hormones and mitogens) may be exceptions to the dose-setting criteria and should be evaluated on a case-by-case basis. The highest dose may also be defined as a dose that produces some indication of toxicity in the bone marrow (e.g. a reduction in the proportion of immature erythrocytes among total erythrocytes in the bone marrow or peripheral blood).

1.5.4. Limit test

If a test at one dose level of at least 2 000 mg/kg body weight using a single treatment, or as two treatments on the same day, produces no observable toxic effects, and if genotoxicity would not be expected based upon data from structurally related substances, then a fully study using three dose levels may not be considered necessary. For studies of a longer duration, the limit dose is 2 000 mg/kg/body weight/day for treatment up to 14 days, and 1 000 mg/kg/body weight/day for treatment longer than 14 days. Expected human exposure may indicate the need for a higher dose level to be used in the limit test.

1.5.5. Administration of doses

The test substance is usually administered by gavage using a stomach tube or a suitable intubation cannula, or by intraperitoneal injection. Other routes of exposure may be acceptable where they can be justified. The maximum volume of liquid that can be administered by gavage or injection at one time depends on the size of the test animal. The volume should not exceed 2 ml/100g body weight. The use of volumes higher can these must be justified. Except for irritating or corrosive substances which will normally reveal exacerbated effects with higher concentrations, variability in test volume should be minimised by adjusting the concentration to ensure a constant volume at all dose levels.

1.5.6. Bone marrow/blood preparation

Bone marrow cells are usually obtained from the femurs or tibias immediately following sacrifice. Commonly, cells are removed from femurs or tibias, prepared and stained using established methods. Peripheral blood is obtained from the tail vein or other appropriate blood vessel. Blood cells are immediately stained supravitally (8) (9) (10) or smear preparations are made and then stained. The used of a DNA specific stain (e.g. acridine orange (14) or Hoechst 33258 plus pyronin-Y (15)) can eliminate some of the artifacts associated with using a non-DNA-specific stain. This advantage does not preclude the use of conventional stains (e.g., Giemsa). Additional systems (e.g. cellulose columns to remove nucleated cells (16)) can also be used provided that these systems have been shown to adequately work for micronucleus preparation in the laboratory.

1.5.7. Analysis

The proportion of immature among total (immature + mature) erythrocytes is determined for each animal by counting a total at least 200 erythrocytes for bone marrow and 1 000 erythrocytes for peripheral blood (17). All slides, including those of positive and negative controls, should be independently coded before microscopic analysis. At least 2 000 immature erythrocytes per animal are scored for the incidence of
micronucleated immature erythrocytes. Additional information may be obtained by scoring mature erythrocytes for micronuclei. When analysing slides, the proportion of immature erythrocytes among total erythrocytes should not be less than 20% of the control value. When animals are treated continuously for four weeks or more, at least 2000 mature erythrocytes per animal can also be scored for the incidence of micronuclei. Systems for automated analysis (image analysis and flow cytometric analysis of cell suspensions) are acceptable alternatives to manual evaluation if appropriately justified and validated.

2. DATA

2.1. TREATMENT OF RESULTS

Individual animal data should be presented in tabular form. The experimental unit is the animal. The number of immature erythrocytes scored, the number of micronucleated immature erythrocytes, and the number of immature among total erythrocytes should be listed separately for each animal analysed. When animals are treated continuously for four weeks or more, the data on mature erythrocytes should also be given if it is collected. The proportion of immature among total erythrocytes and, if considered applicable, the percentage of micronucleated erythrocytes is given for each animal. If there is no evidence for a difference in response between the sexes, the data from both sexes may be combined for statistical analysis.

2.2. EVALUATION AND INTERPRETATION OF RESULTS

There are several criteria for determining a positive result, such as a dose-related increase in the number of micronucleated cells or a clear increase in the number of micronucleated cells in a single dose group at a single sampling time. Biological relevance of the results should be considered first. Statistical methods may be used as an aid in evaluating the test results (18) (19). Statistical significance should not be only determining factor for a positive response. Equivocal results should be clarified by further testing preferably using a modification of experimental conditions.

A test substance for which the results do not meet the above criteria is considered non-mutagenic in this test.

Although most experiments will give clearly positive or negative results, in rare cases the data set will preclude making a definite judgement about the activity of the test substance. Results may remain equivocal or questionable regardless of the number of times the experiment is repeated.

Positive results in the micronucleus test indicate that the substance induces micronuclei which are the result of chromosomal damage or damage to the mitotic apparatus in the erythroblasts of the test species. Negative results indicate that, under the test conditions, the test substance does not produce micronuclei in the immature erythrocytes of the test species.

The likelihood that the test substance or its metabolites reach the general circulation or specifically the target tissue (e.g. systemic toxicity) should be discussed.

3. REPORTING

TEST REPORT

The test report should include the following information:

Solvent/vehicle:

— justification for choice of vehicle,

— solubility and stability of the test substance in solvent/vehicle, if known.
Test animals:
— species/strain used,
— number, age and sex of animals,
— source, housing conditions, diet, etc.,
— individual weight of the animals at the start of the test, including body weight range, mean and standard deviation for each group.

Test conditions:
— positive and negative (vehicle/solvent) control data,
— data from range-finding study, if conducted,
— rationale for dose level selection,
— details of test substance preparation,
— details of the administration of the test substance,
— rationale for route of administration,
— methods for verifying that the test substance reached the general circulation or target tissue, if applicable,
— conversion from diet/drinking water test substance concentration (ppm) to the actual dose (mg/kg body weight/day), if applicable,
— details of food and water quality,
— detailed description of treatment and sampling schedules,
— methods of slide preparation,
— methods for measurements of toxicity,
— criteria for scoring micronucleated immature erythrocytes,
— number of cells analysed per animal,
— criteria for considering studies as positive, negative or equivocal.

Results:
— signs of toxicity,
— proportion of immature erythrocytes among total erythrocytes,
— number of micronucleated immature erythrocytes, given separately for each animal,
— mean ± standard deviation of micronucleated immature erythrocytes per group,
— dose-response relationship, where possible,
— statistical analyses and methods applied,
— concurrent and historical negative data,
— concurrent positive control data.

Discussion of the results.

Conclusions.
4. REFERENCES


ANNEX 4D

'B.13/14. MUTAGENICITY — REVERSE MUTATION TEST BACTERIA

1. METHOD

This method is a replicate of the OECD TG 471, Bacterial Reverse Mutation Test (1997).

1.1. INTRODUCTION

The bacterial reverse mutation test uses amino-acid requiring strains of *Salmonella typhimurium* and *Escherichia coli* to detect point mutations, which involve substitution, addition or deletion of one or a few DNA base pairs (1) (2) (3). The principle of this bacterial reverse mutation test is that it detects mutations which revert mutations present in the test strains and restore the functional capability of the bacteria to synthesise an essential amino acid. The revertant bacteria are detected by their ability to grow in the absence of the amino-acid required by the parent test strain.

Point mutations are the cause of many human genetic diseases and there is substantial evidence that point mutations in oncogenes and tumour suppressor genes of somatic cells are involved in tumour formation in humans and experimental animals. The bacterial reverse mutation test is rapid, inexpensive and relatively easy to perform. Many of the test strains have several features that make them more sensitive for the detection of mutations including responsive DNA sequences at the reversion sites, increased cell permeability to large molecules and elimination of DNA repair systems or enhancement of error-prone DNA repair processes. The specificity of the test strains can provide some useful information on the types of mutations that are induced by genotoxic agents. A very large data base of results for a wide variety of structures is available for bacterial reverse mutation tests and well-established methodologies have been developed for testing chemicals with different physico-chemical properties, including volatile compounds.

See also General Introduction Part B.

1.2. DEFINITIONS

A reverse mutation test in either *Salmonella typhimurium* or *Escherichia coli* detects mutation in an amino acid requiring strain (histidine or tryptophan, respectively) to produce a strain independent of an outside supply of amino acid.

Base pair substitution mutagens are agents that cause a base change in DNA. In a reversion test this change may occur at the site of the original mutation, or at a second site in the bacterial genome.

Frameshift mutagens are agents that cause the addition or deletion of one or more base pairs in the DNA, thus changing the reading frame in the RNA.

1.3. INITIAL CONSIDERATIONS

The bacterial reverse mutation test utilises prokaryotic cells, which differ from mammalian cells in such factors as uptake, metabolism, chromosome structure and DNA repair processes. Tests conducted *in vitro* generally require the use of an exogenous source of metabolic activation. *In vitro* metabolic activation systems cannot mimic entirely the mammalian *in vivo* conditions. The test therefore does not provide direct information on the mutagenic and carcinogenic potency of a substance in mammals.

The bacterial reverse mutation test is commonly employed as an initial screen for genotoxic activity and, in particular, for point mutation-inducing activity. An extensive data base has demonstrated that many chemicals that are positive in this test also exhibit mutagenic activity in other tests. There are examples of mutagenic agents which are not detected by this test; reasons for these shortcomings can be ascribed to the
specific nature of the endpoint detected, differences in metabolic activation, or differences in bioavailability.
On the other hand, factors which enhance the sensitivity of the bacterial reverse mutation test can lead to an
overestimation of mutagenic activity.

The bacterial reverse mutation test may not be appropriate for the evaluation of certain classes of chemicals,
for example highly bactericidal compounds (e.g. certain antibiotics) and those which are thought (or known)
to interfere specifically with the mammalian cell replication system (e.g. some topoisomerase inhibitors and
some nucleoside analogues). In such cases, mammalian mutation tests may be more appropriate.

Although many compounds that are positive in this test are mammalian carcinogens, the correlation is not
absolute. It is dependent on chemical class and there are carcinogens that are not detected by this test
because they act through other, non-genotoxic, mechanisms or mechanisms absent in bacterial cells.

1.4. PRINCIPLES OF THE TEST METHOD

Suspensions of bacterial cells are exposed to the test substance in the presence and in the absence of an
exogenous metabolic activation system. In the plate incorporation method, these suspensions are mixed with
an overlay agar and plated immediately onto minimal medium. In the preincubation method, the treatment
mixture is incubated and then mixed with an overlay agar before plating onto minimal medium. For both
techniques, after two or three days of incubation, revertant colonies are counted and compared to the
number of spontaneous revertant colonies on solvent control plates.

Several procedures for performing the bacterial reverse mutation test have been described. Among those
commonly used are the plate incorporation method (1) (2) (3) (4), the preincubation method (2) (3) (5) (6) (7)
(8), the fluctuation method (9) (10), and the suspension method (11). Modifications for the testing of gases or
vapours have been described (12).

The procedures described in the method pertain primarily to the plate incorporation and preincubation
methods. Either of them is acceptable for conducting experiments both with and without metabolic
activation. Some substances may be detected more efficiently using the preincubation method. These
substances belong to chemical classes that include short chain aliphatic nitrosamines, divalent metals,
aldehydes, azo-dyes and diazo compounds, pyrrolizidine alkaloids, allyl compounds and nitro compounds (3).
It is also recognised that certain classes of mutagens are not always detected using standard procedures such
as the plate incorporation method or preincubation method. These should be regarded as “special cases” and
it is strongly recommended that alternative procedures should be used for their detection. The following
“special cases” could be identified (together with examples of procedures that could be used for their
detection): azo-dyes and diazo compounds (3) (5) (6) (13), gases and volatile chemicals (12) (14) (15) (16) and
glycosides (17) (18). A deviation from the standard procedure needs to be scientifically justified.

1.5. DESCRIPTION OF THE TEST METHOD

1.5.1. Preparations

1.5.1.1. Bacteria

Fresh cultures of bacteria should be grown up to the late exponential or early stationary phase of growth
(approximately 10⁹ cells per ml). Cultures in late stationary phase should not be used. It is essential that the
cultures used in the experiment contain a high titre of viable bacteria. The titre may be demonstrated either
from historical control data on growth curves, or in each assay through the determination of viable cell
numbers by a plating experiment.

The recommended incubation temperature is 37°C.

At least five strains of bacteria should be used. These should include four strains of S. typhimurium (TA 1535;
TA 1537 or TA97a or TA97; TA98; and TA100) that have been shown to be reliable and reproducibly
responsive between laboratories. These four S. typhimurium strains have GC base pairs at the primary
reversion site and it is known that they may not detect certain oxidising mutagens, cross-linking agents and
hydrazines. Such substances may be detected by E. coli WP2 strains or S. typhimurium TA102 (19) which have
an AT base pair at the primary reversion site. Therefore the recommended combination of strains is:
— *S. typhimurium* TA1535, and
— *S. typhimurium* TA1537 or TA97 or TA97a, and
— *S. typhimurium* TA98, and
— *S. typhimurium* TA100, and
— *E. coli* WP2 uvrA, or *E. coli* WP2 uvrA (pKM101), or *S. typhimurium* TA102.

In order to detect cross-linking mutagens it may be preferable to include TA102 or to add a DNA repair-proficient strain of *E. coli* (e.g. *E. coli* WP2 or *E. coli* WP2 (pKM101)).

Established procedures for stock culture preparation, marker verification and storage should be used. The amino-acid requirement for growth should be demonstrated for each frozen stock culture preparation (histidine for *S. typhimurium* strains, and tryptophan for *E. coli* strains). Other phenotypic characteristics should be similarly checked, namely: the presence or absence of R-factor plasmids where appropriate (i.e. ampicillin resistance in strains TA98, TA100, and TA97a or TA97, WP2 uvrA and WP2 uvrA (pKM101), and ampicillin + tetracycline resistance in strain TA 102); the presence of characteristic mutations (i.e. rfa mutation in *S. typhimurium* through sensitivity to crystal violet, and uvrA mutation in *E. coli* or uvrB mutation in *S. typhimurium* through sensitivity to ultra-violet light) (2) (3). The strains should also yield spontaneous revertant colony plate counts within the frequency ranges expected from the laboratory’s historical control data and preferably within the range reported in the literature.

1.5.1.2. Medium

An appropriate minimal agar (e.g. containing Vogel-Bonner minimal medium E and glucose), and an overlay agar containing histidine and biotin or tryptophan to allow for a few cell divisions, is used (1) (2) (9).

1.5.1.3. Metabolic activation

Bacteria should be exposed to the test substance both in the presence and absence of an appropriate metabolic activation system. The most commonly used system is a cofactor-supplemented post-mitochondrial fraction (S9) prepared from the livers of rodents treated with enzyme-inducing agents such as Aroclor 1254 (1) (2) or a combination of phenobarbitone and β-naphthoflavone (18) (20) (21). The post-mitochondrial fraction is usually used at concentrations in the range from 5 to 30% v/v in the S9-mix. The choice and condition of a metabolic activation system may depend upon the class of chemical being tested. In some cases, it may be appropriate to utilise more than one concentration of post-mitochondrial fraction. For azo-dyes and diazo-compounds, using a reductive metabolic activation system may be more appropriate (6) (13).

1.5.1.4. Test substance/preparation

Solid test substances should be dissolved or suspended in appropriate solvents or vehicles and diluted if appropriate prior to treatment of the bacteria. Liquid test substances may be added directly to the test systems and/or diluted prior to treatment. Fresh preparations should be employed unless stability data demonstrate the acceptability of storage.

The solvent/vehicle should not be suspected of chemical reaction with the test substance and should be compatible with the survival of the bacteria and the S9 activity (22). If other than well-known solvent/vehicles are used, their inclusion should be supported by data indicating their compatibility. It is recommended that wherever possible, the use of an aqueous solvent/vehicle be considered first. When testing water-unstable substances, the organic solvents used should be free of water.

1.5.2. Test conditions

1.5.2.1. Test strains (see 1.5.1.1)

1.5.2.2. Exposure concentration

Amongst the criteria to be taken into consideration when determining the highest amount of the test substance to be used are the cytotoxicity and the solubility in the final treatment mixture.
It may be useful to determine toxicity and insolubility in a preliminary experiment. Cytotoxicity may be detected by a reduction in the number of revertant colonies, a clearing or diminution of the background lawn, or the degree of survival of treated cultures. The cytotoxicity of a substance may be altered in the presence of metabolic activation systems. Insolubility should be assessed as precipitation in the final mixture under the actual test conditions and evident to the unaided eye.

The recommended maximum test concentration for soluble non-cytotoxic substances is 5 mg/plate or 5 µl/plate. For non-cytotoxic substances that are not soluble at 5 mg/plate or 5 µl/plate, one or more concentrations tested should be insoluble in the final treatment mixture. Test substances that are cytotoxic already below 5 mg/plate or 5 µl/plate should be tested up to a cytotoxic concentration. The precipitate should not interfere with the scoring.

At least five different analysable concentrations of the test substance should be used with approximately half log (i.e., \(10^{0.5}\)) intervals between test points for an initial experiment. Smaller intervals may be appropriate when a concentration-response is being investigated. Testing above the concentration of 5 mg/plate or 5 µl/plate may be considered when evaluating substances containing substantial amounts of potentially mutagenic impurities.

1.5.2.3. Negative and positive controls

Concurrent strain-specific positive and negative (solvent or vehicle) controls, both with and without metabolic activation, should be included in each assay. Positive control concentrations that demonstrate the effective performance of each assay should be selected.

For assays employing a metabolic activation system, the positive control reference substance(s) should be selected on the basis of the type of bacteria strains used.

The following substances are examples of suitable positive controls for assays with metabolic activation:

<table>
<thead>
<tr>
<th>Substance</th>
<th>CAS No</th>
<th>Einecs No</th>
</tr>
</thead>
<tbody>
<tr>
<td>9,10-dimethylanthracene</td>
<td>781-43-1</td>
<td>212-308-4</td>
</tr>
<tr>
<td>7,12-dimethylbenz[a]anthracene</td>
<td>57-97-6</td>
<td>200-359-5</td>
</tr>
<tr>
<td>benzo[a]pyrene</td>
<td>50-32-8</td>
<td>200-028-5</td>
</tr>
<tr>
<td>2-aminoanthracene</td>
<td>613-13-8</td>
<td>210-330-9</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>50-18-0</td>
<td>200-015-4</td>
</tr>
<tr>
<td>cyclophosphamide monohydrate</td>
<td>6055-19-2</td>
<td></td>
</tr>
</tbody>
</table>

The following substance is a suitable positive control for the reductive metabolic activation method:

<table>
<thead>
<tr>
<th>Substance</th>
<th>CAS No</th>
<th>Einecs No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congo Red</td>
<td>573-58-0</td>
<td>209-358-4</td>
</tr>
</tbody>
</table>

2-Aminoanthracene should not be used as the sole indicator of the efficacy of the S9-mix. If 2-aminoanthracene is used, each batch of S9 should also be characterised with a mutagen that requires metabolic activation by microsomal enzymes, e.g., benzo[a]pyrene, dimethylbenzanthracene.
The following substances are examples of strain-specific positive controls for assays performed without exogenous metabolic activation system:

<table>
<thead>
<tr>
<th>Substance</th>
<th>CAS No</th>
<th>Einecs No</th>
<th>Strain</th>
</tr>
</thead>
<tbody>
<tr>
<td>sodium azide</td>
<td>26628-22-8</td>
<td>247-852-1</td>
<td>TA 1535 and TA 100</td>
</tr>
<tr>
<td>2-nitrofluorene</td>
<td>607-57-8</td>
<td>210-138-5</td>
<td>TA 98</td>
</tr>
<tr>
<td>9-aminoacridine</td>
<td>90-45-9</td>
<td>201-995-6</td>
<td>TA 1537, TA 97 and TA 97a</td>
</tr>
<tr>
<td>ICR 191</td>
<td>17070-45-0</td>
<td>241-129-4</td>
<td>TA 1537, TA 97 and TA 97a</td>
</tr>
<tr>
<td>cumene hydroperoxide</td>
<td>80-15-9</td>
<td>201-254-7</td>
<td>TA 102</td>
</tr>
<tr>
<td>mitomycin C</td>
<td>50-07-7</td>
<td>200-008-6</td>
<td>WP2 uvrA and TA 102</td>
</tr>
<tr>
<td>N-ethyl-N-nitro-N-nitrosoguanidine</td>
<td>70-25-7</td>
<td>200-730-1</td>
<td>WP2, WP2uvrA and WP2uvrA(pKM101)</td>
</tr>
<tr>
<td>4-nitroquinoline-1-oxide</td>
<td>56-57-5</td>
<td>200-281-1</td>
<td>WP2, WP2uvrA and WP2uvrA(pKM101)</td>
</tr>
<tr>
<td>furylfuramide (AF2)</td>
<td>3688-53-7</td>
<td></td>
<td>plasmid-containing strains</td>
</tr>
</tbody>
</table>

Other appropriate positive control reference substances may be used. The use of chemical class-related positive control chemicals should be considered, when available.

Negative controls, consisting of solvent or vehicle alone, without test substance, and otherwise treated in the same way as the treatment groups, should be included. In addition, untreated controls should also be used unless there are historical control data demonstrating that no deleterious or mutagenic effects are induced by the chosen solvent.

1.5.3. Procedure

For the plate incorporation method (1) (2) (3) (4), without metabolic activation, usually 0.05 ml or 0.1 ml of the test solutions, 0.1 ml of fresh bacterial culture (containing approximately 10⁸ viable cells) and 0.5 ml of sterile buffer are mixed with 2.0 ml of overlay agar. For the assay with metabolic activation, usually 0.5 ml of metabolic activation mixture containing an adequate amount of post-mitochondrial fraction (in the range from 5 to 30% v/v in the metabolic activation mixture) are mixed with the overlay agar (2.0 ml), together with the bacteria and test substance/test solution. The contents of each tube are mixed and poured over the surface of a minimal agar plate. The overlay agar is allowed to solidify before incubation.

For the preincubation method (2) (3) (5) (6), the test substance/test solution is preincubated with the test strain (containing approximately 10⁸ viable cells) and sterile buffer or the metabolic activation system (0.5 ml) usually for 20 minutes or more at 30–37°C prior to mixing with the overlay agar and pouring onto the surface of a minimal agar plate. Usually 0.05 or 0.1 ml of test substance/test solution, 0.1 ml of bacteria and 0.5 ml of S9-mix or sterile buffer are mixed with 2.0 ml of overlay agar. Tubes should be aerated during pre-incubation by using a shaker.

For an adequate estimate of variation, triplicate plating should be used at each dose level. The use of duplicate plating is acceptable when scientifically justified. The occasional loss of a plate does not necessarily invalidate the assay.

Gaseous or volatile substances should be tested by appropriate methods, such as in sealed vessels (12) (14) (15) (16).
1.5.4. Incubation

All plates in a given assay should be incubated at 37 °C for 48–72 hours. After the incubation period, the number of revertant colonies per plate is counted.

2. DATA

2.1. TREATMENT OF RESULTS

Data should be presented as the number of revertant colonies per plate. The number of revertant colonies on both negative (solvent control, and untreated control if used) and positive control plates should also be given. Individual plate counts, the mean number of revertant colonies per plate and the standard deviation should be presented for the test substance and positive and negative (untreated and/or solvent) controls.

There is no requirement for verification of a clear positive response. Equivocal results should be clarified by further testing preferably using a modification of experimental conditions. Negative results need to be confirmed on a case-by-case basis. In those cases where confirmation of negative results is not considered necessary, justification should be provided. Modification of study parameters to extend the range of conditions assessed should be considered in follow-up experiments. Study parameters that might be modified include the concentration spacing, the method of treatment (plate-incorporation or liquid pre-incubation), and metabolic activation conditions.

2.2. EVALUATION AND INTERPRETATION OF RESULTS

There are several criteria for determining a positive result, such as a concentration-related increase over the range tested and/or a reproducible increase at one or more concentrations in the number of revertant colonies per plate in at least one strain with or without metabolic activation system (23). Biological relevance of the results should be considered first. Statistical methods may be used as an aid in evaluating the test results (24). However, statistical significance should not be the only determining factor for a positive response.

A test substance for which the results do not meet the above criteria is considered non-mutagenic in this test.

Although most experiments will give clearly positive or negative results, in rare cases the data set will preclude making a definite judgement about the activity of the test substance. Results may remain equivocal or questionable regardless of the number of times the experiment is repeated.

Positive results from the bacterial reverse mutation test indicate that the substance induces point mutations by base substitutions or frameshifts in the genome of either Salmonella typhimurium and/or Escherichia coli. Negative results indicate that under the test conditions, the test substance is not mutagenic in the tested species.

3. REPORTING

TEST REPORT

The test report must include the following information:

Solvent/vehicle:
— justification for choice of solvent/vehicle,
— solubility and stability of the test substance in solvent/vehicle, if known.

Strains:
— strains used,
— number of cells per culture,
— strain characteristics.
Test conditions:

— amount of test substance per plate (mg/plate or µl/plate) with rationale for selection of dose and number of plates per concentration,
— media used,
— type and composition of metabolic activation system, including acceptability criteria,
— treatment procedures.

Results:

— signs of toxicity,
— signs of precipitation,
— individual plate counts,
— the mean number of revertant colonies per plate and standard deviation,
— dose-response relationship, where possible,
— statistical analyses, if any,
— concurrent negative (solvent/vehicle) and positive control data, with ranges, means and standard deviations,
— historical negative (solvent/vehicle) and positive control data with ranges, means and standard deviations.

Discussion of results.

Conclusions.

4. REFERENCES


(9) Green, M. H. L., Muriel, W. J. and Bridges, B. A. (1976), Use of a simplified fluctuation test to detect low levels of mutagens, *Mutation Res.*, 38, pp. 33–42.


ANNEX 4E

‘B.17. MUTAGENICITY — IN VITRO MAMMALIAN CELL GENE MUTATION TEST

1. METHOD

This method is a replicate of the OECD TG 476, In Vitro Mammalian Cell Gene Mutation Test (1997).

1.1. INTRODUCTION

The in vitro mammalian cell gene mutation test can be used to detect gene mutations induced by chemical substances. Suitable cell lines include L5178Y mouse lymphoma cells, the CHO, CHO-A52 and V79 lines of Chinese hamster cells, and TK6 human lymphoblastoid cells (1). In these cell lines the most commonly used genetic endpoints measure mutation at thymidine kinase (TK) and hypoxanthine-guanine phosphoribosyl transferase (HPRT), and a transgene of xanthine-guanine phosphoribosyl transferase (XPRT). The TK, HPRT and XPRT mutation tests detect different spectra of genetic events. The autosomal location of TK and XPRT may allow the detection of genetic events (e.g. large deletions) not detected at the HPRT locus on X chromosomes (2)(3)(4)(5)(6).

In the in vitro mammalian cell gene mutation test, cultures of established cell lines or cell strains can be used. The cells used are selected on the basis of growth ability in culture and stability of the spontaneous mutation frequency.

Tests conducted in vitro generally require the use of an exogenous source of metabolic activation. This metabolic activation system cannot mimic entirely the mammalian in vivo conditions. Care should be taken to avoid conditions which would lead to results not reflecting intrinsic mutagenicity. Positive results which do not reflect intrinsic mutagenicity may arise from changes in pH, osmolality or high levels of cytotoxicity (7).

This test is used to screen for possible mammalian mutagens and carcinogens. Many compounds that are positive in this test are mammalian carcinogens; however, there is not a perfect correlation between this test and carcinogenicity. Correlation is dependent on chemical class and there is increasing evidence that there are carcinogens that are not detected by this test because they appear to act through other, non-genotoxic mechanisms or mechanisms absent in bacterial cells (6).

See also General Introduction Part B:

1.2. DEFINITIONS

Forward mutation: a gene mutation from the parental type of the mutant form which gives rise to an alteration or a loss of the enzymatic activity of the function of the encoded protein.

Base pair substitution mutagens: substances which cause substitution of one or several base pairs in the DNA.

Frameshift mutagens: Substances which cause the addition or deletion of single or multiple base pairs in the DNA molecule.

Phenotypic expression time: a period during which unaltered gene products are depleted from newly mutated cells.

Mutant frequency: the number of mutant cells observed divided by the number of viable cells.

Relative total growth: increase in cell number over time compared to a control population of cells; calculated as the product of suspension growth relative to the negative control times cloning efficiency relative to negative control.

Relative suspension growth: increase in cell number over the expression period relative to the negative control.
**Viability:** the cloning efficiency of the treated cells at the time of plating in selective conditions after the expression period.

**Survival:** the cloning efficiency of the treated cells when plated at the end of the treatment period; survival is usually expressed in relation to the survival of the control cell population.

1.3. **PRINCIPLE OF THE TEST METHOD**

Cells deficient in thymidine kinase (TK) due to the mutation TK<sup>−/−</sup> → TK<sup>+</sup> are resistant to the cytotoxic effects of the pyrimidine analogue trifluorothymidine (TFT). Thymidine kinase proficient cells are sensitive to TFT, which causes the inhibition of cellular metabolism and halts further cell division. Thus mutant cells are able to proliferate in the presence of TFT, whereas normal cells, which contain thymidine kinase, are not. Similarly, cells deficient in HPRT or XPRT are selected by resistance to 6-thioguanine (TG) or 8-azaguanine (AG). The properties of the test substance should be considered carefully if a base analogue or a compound related to the selective agent is tested in any of the mammalian cell gene mutation tests. For example, any suspected selective toxicity by the test substance for mutant and non-mutant cells should be investigated. Thus, performance of the selection system/agent must be confirmed when testing chemicals structurally related to the selective agent (8).

Cells in suspension or monolayer culture are exposed to the test substance, both with and without metabolic activation, for a suitable period of time and subcultured to determine cytotoxicity and to allow phenotypic expression prior to mutant selection (9) (10) (11) (12) (13). Cytotoxicity is usually determined by measuring the relative cloning efficiency (survival) or relative total growth of the cultures after the treatment period. The treated cultures are maintained in growth medium for a sufficient period of time, characteristic of each selected locus and cell type, to allow near-optimal phenotypic expression of induced mutations. Mutant frequency is determined by seeding known numbers of cells in medium containing the selective agent to detect mutant cells and in medium without selective agent to determine the cloning efficiency (viability). After a suitable incubation time, colonies are counted. The mutant frequency is derived from the number of mutant colonies in selective medium and the number of colonies in non-selective medium.

1.4. **DESCRIPTION OF THE TEST METHOD**

1.4.1. **Preparations**

1.4.1.1. **Cells**

A variety of cell types are available for use in this test including subclones of L5171Y, CHO, CHO-AS52, V79 or TK6 cells. Cell types used in this test should have a demonstrated sensitivity to chemical mutagens, a high cloning efficiency and a stable spontaneous mutant frequency. Cells should be checked for mycoplasma contamination and should not be used if contaminated.

The test should be designed to have a predetermined sensitivity and power. The number of cells, cultures and concentrations of test substance used should reflect these defined parameters (14). The minimal number of viable cells surviving treatment and used at each stage in the test should be based on the spontaneous mutation frequency. A general guide is to use a cell number which is at least 10 times the inverse of the spontaneous mutation frequency. However, it is recommended to utilise at least 10<sup>6</sup> cells. Adequate historical data on the cell system used should be available to indicate consistent performance of the test.

1.4.1.2. **Media and culture conditions**

Appropriate culture media, and incubation conditions (culture vessels, temperature, CO<sub>2</sub> concentration and humidity) should be used. Media should be chosen according to the selective systems and cell type used in the test. It is particularly important that culture conditions should be chosen that ensure optimal growth of cells during the expression period and colony forming ability of both mutant and non-mutant cells.
1.4.1.3. Preparation of cultures

Cells are propagated from stock cultures, seeded in culture medium and incubated at 37 °C. Prior to use in this test, cultures may need to be cleansed of pre-existing mutant cells.

1.4.1.4. Metabolic activation

Cells should be exposed to the test substance both in the presence and absence of an appropriate metabolic activation system. The most commonly used system is a cofactor-supplemented post-mitochondrial fraction (S9) prepared from the livers of rodents treated with enzyme-inducing agents such as Aroclor 1254 (15) (16) (17) (18) or a combination of phenobarbitone and β-naphthoflavone (19) (20).

The post-mitochondrial fraction is usually used at concentrations in the range from 1—10 % v/v in the final test medium. The choice and condition of a metabolic activation system may depend upon the class of chemical being tested. In some cases it may be appropriate to utilise more than one concentration of post-mitochondrial fraction.

A number of developments, including the construction of genetically engineered cell lines expressing specific activating enzymes, may provide the potential for endogenous activation. The choice of the cell lines used should be scientifically justified (e.g. by the relevance of the cytochrome P450 isoenzyme for the metabolism of the test substance).

1.4.1.5. Test substance preparation

Solid test substances should be dissolved or suspended in appropriate solvents or vehicles and diluted if appropriate prior to treatment of the cells. Liquid test substances may be added directly to the test systems and/or diluted prior to treatment. Fresh preparations of the test substance should be employed unless stability data demonstrate the acceptability of storage.

1.4.2. Test conditions

1.4.2.1. Solvent/vehicle

The solvent/vehicle should not be suspected of chemical reaction with the test substance and should be compatible with the survival of the cells and the S9 activity. If other than well-known solvent/vehicles are used, their inclusion should be supported by data indicating their compatibility. It is recommended that wherever possible, the use of an aqueous solvent/vehicle be considered first. When testing water-unstable substances, the organic solvents used should be free of water. Water can be removed by adding a molecular sieve.

1.4.2.2. Exposure concentrations

Among the criteria to be considered when determining the highest concentration are cytotoxicity, solubility in the test system and changes in pH or osmolality.

Cytotoxicity should be determined with and without metabolic activation in the main experiment using an appropriate indication of cell integrity and growth, such as relative cloning efficiency (survival) or relative total growth. It may be useful to determine cytotoxicity and solubility in a preliminary experiment.

At last four analysable concentrations should be used. Where there is cytotoxicity, these concentrations should cover a range from the maximum to little or no toxicity; this will usually mean that the concentration levels should be separated by no more than a factor between 2 and 10. If the maximum concentration is based on cytotoxicity then it should result in approximately 10—20 % (but not less than 10 %) relative survival (relative cloning efficiency) or relative total growth. For relatively non-cytotoxic substances, the maximum test concentration should be 5 mg/ml, 5 µl/ml, or 1,01 M, whichever is the lowest.

Relatively insoluble substances should be tested up to or beyond their limit of solubility under culture conditions. Evidence of insolubility should be determined in the final treatment medium to which cells are exposed. It may be useful to assess solubility at the beginning and the end of the treatment, as solubility can change during the course of exposure in the test system due to presence of cells, S9, serum etc. Insolubility can be detected by using the unaided eye. The precipitate should not interfere with the scoring.
1.4.2.3. Controls

Concurrent positive and negative (solvent or vehicle) controls, both with and without metabolic activation should be included in each experiment. When metabolic activation is used, the positive control chemical should be the one that requires activation to give a mutagenic response.

Examples of positive control substances include:

<table>
<thead>
<tr>
<th>Metabolic activation condition</th>
<th>Locus</th>
<th>Substance</th>
<th>CAS No</th>
<th>Einecs No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of exogenous</td>
<td>HPRT</td>
<td>3-Methylcholanthrene</td>
<td>56-49-5</td>
<td>200-276-4</td>
</tr>
<tr>
<td>mutant-like activity</td>
<td></td>
<td>N-Nitrosodimethylamine</td>
<td>62-75-9</td>
<td>200-549-8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7,12-Dimethylbenzanthracene</td>
<td>57-97-6</td>
<td>200-359-5</td>
</tr>
<tr>
<td>TK (small and large colonies)</td>
<td></td>
<td>Cyclophosphamide</td>
<td>50-18-0</td>
<td>200-015-4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cyclophosphamide monohydrate</td>
<td>6055-19-2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Benzo[a]pyrene</td>
<td>50-32-8</td>
<td>200-028-5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3-Methylcholanthrene</td>
<td>56-49-5</td>
<td>200-276-5</td>
</tr>
<tr>
<td></td>
<td>XPRT</td>
<td>N-Nitrosodimethylamine (for high levels of S-9)</td>
<td>62-75-9</td>
<td>200-549-8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Benzo[a]pyrene</td>
<td>50-32-8</td>
<td>200-028-5</td>
</tr>
</tbody>
</table>

Other appropriate positive control reference substances may be used, e.g. if a laboratory has a historical database on 5-bromo 2’-deoxyuridine (CAS No 59-14-3, Einecs No 200-415-9), this reference substance could be used as well. The use of chemical class-related positive control chemicals should be considered, when available.

Negative controls, consisting of solvent or vehicle alone in the treatment medium, and treated in the same way as the treatment groups, should be included. In addition, untreated controls should also be used unless there are historical control data demonstrating that no deleterious or mutagenic effects are induced by the chosen solvent.

1.4.3. Procedure

1.4.3.1. Treatment with the test substance

Proliferating cells should be exposed to the test substance both with and without metabolic activation. Exposure should be for a suitable period of time (usually 3—6 hours is effective). Exposure time may be extended over once or more cell cycles.
Either duplicate or single treated cultures may be used at each concentration tested. When single cultures are used, the number of concentrations should be increased to ensure an adequate number of cultures for analysis (e.g. at least eight analysable concentrations). Duplicate negative (solvent) control cultures should be used.

Gaseous or volatile substances should be tested by appropriate methods, such as in scaled culture vessels (21) (22).

1.4.3.2. Measurement of survival, viability and mutant frequency

At the end of the exposure period, cells are washed and cultured to determine survival and to allow for expression of the mutant phenotype. Measurement of cytotoxicity by determining the relative cloning efficiency (survival) or relative total growth of the cultures is usually initiated after the treatment period.

Each locus has a defined minimum time requirement to allow near optimal phenotypic expression of newly induced mutants (HPRT and XPR require at least 6-8 days, and TK at least two days). Cells are grown in medium with and without selective agent(s) for determination of numbers of mutants and cloning efficiency, respectively. The measurement of viability (used to calculate mutant frequency) is initiated at the end of the expression time by plating in non-selective medium.

If the test substance is positive in the L5178Y TK+/fl test, colony sizing should be performed on at least one of the test cultures (the highest positive concentration) and on the negative and positive controls. If the test substance is negative in the L5178Y TK+/fl test, colony sizing should be performed on the negative and positive controls. In studies using TK6TK+/fl, colony sizing may also be performed.

2. DATA

2.1. TREATMENT OF RESULTS

Data should include cytotoxicity and viability determination, colony counts and mutant frequencies for the treated and control cultures. In the case of a positive response in the L5178Y TK+/fl test, colonies are scored using the criteria of small and large colonies on at least one concentration of the test substance (highest positive concentration) and on the negative and positive control. The molecular and cytogenetic nature of both large and small colony mutants has been explored in detail (23) (24). In the TK+/fl test, colonies are scored using the criteria of normal growth (large) and slow growth (small) colonies (25). Mutant cells that have suffered the most extensive genetic damage have prolonged doubling times and thus form small colonies. This damage typically ranges in scale from the losses of the entire gene to karyotypically visible chromosome aberrations. The induction of small colony mutants has been associated with chemicals that induce gross chromosome aberrations (26). Less seriously affected mutant cells grow at rates similar to the parental cells and form large colonies.

Survival (relative cloning efficiencies) or relative total growth should be given. Mutant frequency should be expressed as number of mutant cells per number of surviving cells.

Individual culture data should be provided. Additionally, all data should be summarised in tabular form.

There is no requirement for verification of a clear positive response. Equivocal results should be clarified by further testing preferably using modification of experimental conditions. Negative results need to be confirmed on a case-by-case basis. In those cases where confirmation of negative results is not considered necessary, justification should be provided. Modification of study parameters to extend the range of conditions assessed should be considered in follow-up experiments for either equivocal or negative results. Study parameters that might be modified include the concentration spacing and the metabolic activation conditions.

2.2. EVALUATION AND INTERPRETATION OF RESULTS

There are several criteria for determining a positive result, such as a concentration-related increase or a reproducible increase in mutant frequency. Biological relevance of the results should be considered first. Statistical methods may be used as an aid in evaluating the test results. Statistical significance should not be the only determining factor for a positive response.
A test substance for which the results do not meet the above criteria is considered non-mutagenic in this system.

Although most studies will give clearly positive or negative results, in rare cases the data set will preclude making a definite judgement about the activity of the test substance. Results may remain equivocal or questionable regardless of the number of times the experiment is repeated.

Positive results from the \textit{in vitro} mammalian cell gene mutation test indicate that the test substance induces gene mutations in the cultured mammalian cells used. A positive concentration-response that is reproducible is most meaningful. Negative results indicate that, under the test conditions, the test substance does not induce gene mutations in the cultured mammalian cells used.

3. REPORTING

TEST REPORT

The test report must include the following information:

Solvent/vehicle:
- justification for choice of vehicle/solvent,
- solubility and stability of the test substance in solvent/vehicle, if known.

Cells:
- type and source of cells,
- number of cell cultures,
- number of cell passages, if applicable,
- methods for maintenance of cell culture, if applicable,
- absence of mycoplasma.

Test conditions:
- rationale for selection of concentrations and number of cultures including, e.g. cytotoxicity data and solubility limitations, if available,
- composition of media, CO\textsubscript{2} concentration,
- concentration of test substance,
- volume of vehicle and test substance added,
- incubation temperature,
- incubation time,
- duration of treatment,
- cell density during treatment,
- type and composition of metabolic activation system, including acceptability criteria,
- positive and negative controls,
- length of expression period (including number of cells seeded, and subcultures and feeding schedules, if appropriate),
- selective agents,
- criteria for considering tests as positive, negative or equivocal,
methods used to enumerate numbers of viable and mutant cells,

definition of colonies of which size and type are considered (including criteria for "small" and "large" colonies, as appropriate).

Results:

- signs of toxicity,
- signs of precipitation,
- data on pH and osmolality during the exposure to the test substance, if determined,
- colony size if scored for at least negative and positive controls,
- laboratory's adequacy to detect small colony mutants with the L5178Y TK<sup>−</sup> system where appropriate,
- dose-response relationship, where possible,
- statistical analyses, if any,
- concurrent negative (solvent/vehicle) and positive control data,
- historical negative (solvent/vehicle) and positive control data with ranges, means and standard deviations,
- mutant frequency.

Discussion of results.

Conclusions.

4. REFERENCES


ANNEX 4F

'B.23. MAMMALIAN SPERMATOGONIAL CHROMOSOME ABERRATION TEST

1. METHOD

This method is a replicate of the OECD TG 483, Mammalian Spermatogonial Chromosome Aberration Test (1997).

1.1. INTRODUCTION

The purpose of the in vivo mammalian spermatogonial chromosome aberration test is to identify those substances that cause structural chromosome aberrations in mammalian spermatogonial cells (1) (2) (3) (4) (5). Structural aberrations may be of two types, chromosome or chromatid. With the majority of chemical mutagens, induced aberrations are of the chromatid type, but chromosome-type aberrations also occur. This method is not designed to measure numerical aberrations and is not routinely used for that purpose. Chromosome mutations and related events are the cause of many human genetic diseases.

This test measures chromosome events in spermatogonial germ cells and is, therefore, expected to be predictive of induction of inheritable mutations in germ cells.

Rodents are routinely used in this test. This in vivo cytogenetic test detects chromosome aberrations in spermatogonial mitoses. Other target cells are not the subject of this method.

To detect chromatid-type aberrations in spermatogonial cells, the first mitotic cell division following treatment should be examined before these lesions are lost in subsequent cell divisions. Additional information from treated spermatogonial stem cells can be obtained by meiotic chromosome analysis for chromosome-type aberrations at diakinesis-metaphase I when the treated cells become spermatocytes.

This in vivo test is designed to investigate whether somatic cell mutagens are also active in germ cells. In addition, the spermatogonial test is relevant to assessing mutagenicity hazard in that it allows consideration of factors of in vivo metabolism, pharmacokinetics and DNA repair processes.

A number of generations of spermatogonia are present in the testis with a spectrum of sensitivity to chemical treatment. Thus, the aberrations detected represent an aggregate response of treated spermatogonial cell populations, with the more numerous differentiated spermatogonial cells predominating. Depending on their position within the testis, different generations of spermatogonia may or may not be exposed to the general circulation, because of the physical and physiological Sertoli cell barrier and the blood-testis barrier.

If there is evidence that the test substance, or a reactive metabolite, will not reach the target tissue, it is not appropriate to use this test.

See also General Introduction Part B.

1.2. DEFINITIONS

Chromatid-type aberration: structural chromosome damage expressed as breakage of single chromatids or breakage and reunion between chromatids.

Chromosome-type aberration: structural chromosome damage expressed as breakage, or breakage and reunion, of both chromatids at an identical site.

Gap: an achromatic lesion smaller than the width of one chromatid, and with minimum misalignment of the chromatids.

Numerical aberration: a change in the number of chromosomes from the normal number characteristic of the animals utilised.
Polyploidy: a multiple of the haploid chromosome number \((n)\) other than the diploid number \((2n)\) and so on.

Structural aberration: a change in chromosome structure detectable by microscopic examination of the metaphase stage of cell division, observed as deletions, intrachanges or interchanges.

1.3. PRINCIPLE OF THE TEST METHOD

Animals are exposed to the test substance by an appropriate route of exposure and are sacrificed at appropriate times after treatment. Prior to sacrifice, animals are treated with a metaphase-arresting substance (e.g. colchicine or Colcemid\textsuperscript{®}). Chromosome preparations are then made from germ cells and stained, and metaphase cells are analysed for chromosome aberrations.

1.4. DESCRIPTION OF THE TEST METHOD

1.4.1. Preparations

1.4.1.1. Selection of animal species

Male Chinese hamsters and mice are commonly used. However, males of other appropriate mammalian species may be used. Commonly used laboratory strains of young healthy adult animals should be employed. At the commencement of the study the weight variation of animals should be minimal and not exceed \(+\) 20\% of the mean weight.

1.4.1.2. Housing and feeding conditions

General conditions referred in the General Introduction to Part B are applied although the aim for humidity should be 50—60\%.

1.4.1.3. Preparation of the animals

Healthy young adult males are randomly assigned to the control and treatment groups. Cages should be arranged in such a way that possible effects due to cage placement are minimised. The animals are identified uniquely. The animals are acclimated to the laboratory conditions for at least five days prior to the start of the study.

1.4.1.4. Preparation of doses

Solid test substance should be dissolved or suspended in appropriate solvents or vehicles and diluted, if appropriate, prior to dosing of the animals. Liquid test substances may be dosed directly or diluted prior to dosing. Fresh preparations of the test substance should be employed unless stability data demonstrate the acceptability of storage.

1.4.2. Test conditions

1.4.2.1. Solvent/vehicle

The solvent/vehicle should not produce toxic effects at the dose levels used and should not be suspected of chemical reaction with the test substance. If other than well-known solvents/vehicles are used, their inclusion should be supported by data indicating their compatibility. It is recommended that wherever possible, the use of an aqueous solvent/vehicle should be considered first.

1.4.2.2. Controls

Concurrent positive and negative (solvent/vehicle) controls should be included in each test. Except for treatment with the test substance, animals in the control groups should be handled in an identical manner to animals in the treated groups.
Positive controls should produce structural chromosome aberrations in vivo in spermatogonial cells when administered at exposure levels expected to give a detectable increase over background.

Positive control doses should be chosen so that the effects are clear but do not immediately reveal the identity of the coded slides to the reader. It is acceptable that the positive control be administered by a route different from the test substance and sampled at only a single time. In addition, the use of chemical class-related positive control chemicals may be considered, when available. Examples of positive control substances include:

<table>
<thead>
<tr>
<th>Substance</th>
<th>CAS No</th>
<th>Einecs No</th>
</tr>
</thead>
<tbody>
<tr>
<td>cyclophosphamide</td>
<td>50-18-0</td>
<td>200-015-4</td>
</tr>
<tr>
<td>cyclophosphamide monohydrate</td>
<td>6055-19-2</td>
<td></td>
</tr>
<tr>
<td>cyclohexylamine</td>
<td>108-91-8</td>
<td>203-629-0</td>
</tr>
<tr>
<td>mitomycin C</td>
<td>50-07-7</td>
<td>200-008-6</td>
</tr>
<tr>
<td>monomeric acrylamide</td>
<td>79-06-1</td>
<td>201-173-7</td>
</tr>
<tr>
<td>triethylenemelamine</td>
<td>51-18-3</td>
<td>200-083-5</td>
</tr>
</tbody>
</table>

Negative controls, treated with solvent or vehicle alone, and otherwise treated in the same way as the treatment groups, should be included for every sampling time, unless acceptable inter-animal variability and frequency of cells with chromosome aberrations are demonstrated by historical control data. In addition, untreated controls should also be used unless there are historical or published control data demonstrating that no deleterious or mutagenic effects are induced by the chosen solvent/vehicle.

1.5. PROCEDURE

1.5.1. Number of animals

Each treated and control group must include at least five analysable males.

1.5.2. Treatment schedule

Test substances are preferably administered once or twice (i.e. as a single treatment or as two treatments). Test substances may also be administered as a split dose, i.e. two treatments on the same day separated by no more than a few hours, to facilitate administering a large volume of material. Other dose regimens should be scientifically justified.

In the highest dose group two sampling times after treatment are used. Since cell cycle kinetics can be influenced by the test substance, one early and one late sampling time are used around 24 and 48 hours after treatment. For doses other than the highest dose, a sampling time of 24 hours or 1.5 cell cycle length after treatment should be taken, unless another sampling time is known to be more appropriate for detection of effects (6).

In addition, other sampling times may be used. For example in the case of chemicals which may induce chromosome lagging, or may exert S-independent effects, earlier sampling times may be appropriate (1).

The appropriateness of a repeated treatment schedule needs to be identified on a case-by-case basis. Following a repeated treatment schedule the animals should then be sacrificed 24 hours (1.5 cell cycle length) after the last treatment. Additional sampling times may be used where appropriate.

Prior to sacrifice, animals are injected intraperitoneally with an appropriate dose of a metaphase arresting substance (e.g. Colcemid® or colchocine). Animals are sampled at an appropriate interval thereafter. For mice this interval is approximately 3—5 hours, for Chinese hamsters this interval is approximately 4—5 hours.
1.5.3. **Dose levels**

If a range finding study is performed because there are no suitable data available, it should be performed in the same laboratory, using the same species, strain and treatment regimen to be used in the main study (7). If there is toxicity, three dose levels are used for the first sampling time. These dose levels should cover a range from the maximum to little or no toxicity. At the later sampling time only the highest dose needs to be used. The highest dose is defined as the dose-producing signs of toxicity such that higher dose levels, based on the same dosing regimen, would be expected to produce lethality.

Substances with specific biological activities at low non-toxic doses (such as hormones and mitogens) may be exceptions to the dose-setting criteria and should be evaluated on a case-by-case basis. The highest dose may also be defined as a dose that produces some indication of toxicity in the spermatogonial cells (e.g. a reduction in the ratio of spermatogonial mitoses to first and second meiotic metaphases; this reduction should not exceed 50%).

1.5.4. **Limit test**

If a test at one dose level of at least 2 000 mg/kg body weight/day using a single treatment, or as two treatments on the same day, produces no observable toxic effects, and if genotoxicity would not be expected based upon data from structurally related substances, then a full study using three dose levels may not be considered necessary. Expected human exposure may indicate the need for a higher dose level to be used in the limit test.

1.5.5. **Administration of doses**

The test substance is usually administered by gavage using a stomach tube or a suitable intubation cannula, or by intraperitoneal injection. Other routes of exposure may be acceptable where they can be justified. The maximum volume of liquid that can be administered by gavage or injection at one time depends on the size of the test animal. The volume should not exceed 2 ml/100g body weight. The use of volumes higher than these must be justified. Except for irritating or corrosive substances, which will normally reveal exacerbated effects with higher concentrations, variability in test volume should be minimised by adjusting the concentration to ensure a constant volume at all dose levels.

1.5.6. **Chromosome preparation**

Immediately after sacrifice, cell suspensions are obtained from one or both testes, exposed to hypotonic solution and fixed. The cells are then spread on slides and stained.

1.5.7. **Analysis**

For each animal at least 100 well-spread metaphase should be analysed (i.e. a minimum of 500 metaphases per group). This number could be reduced when high numbers of aberrations are observed. All slides, including those of positive and negative controls, should be independently coded before microscopic analysis. Since fixation procedures often result in the breakage of a proportion of metaphases with loss of chromosomes, the cells scored should contain a number of centromeres equal to the number $2n \pm 2$.

2. **DATA**

2.1. **TREATMENT OF RESULTS**

Individual animal data should be presented in a tabular form. The experimental unit is the animal. For each individual animal the number of cells with structural chromosome aberrations and the number of chromosome aberrations per cell should be evaluated. Different types of structural chromosome aberrations should be listed with their numbers and frequencies for treated and control groups. Gaps are recorded separately and reported but generally not included in the total aberration frequency.

If mitosis as well as meiosis is observed, the ratio of spermatogonial mitoses to first and second meiotic metaphases should be determined as a measure of cytotoxicity for all treated and negative control animals in a total sample of 100 dividing cells per animal to establish a possible cytotoxic effect. If only mitosis is observed, the mitosis index should be determined in at least 1 000 cells for each animal.
2.2. EVALUATION AND INTERPRETATION OF RESULTS

There are several criteria for determining a positive result, such as a dose-related increase in the relative number of cells with chromosome aberrations or a clear increase in the number of cells with aberrations in a single dose at a single sampling time. Biological relevance of the results should be considered first. Statistical methods may be used as an aid in evaluating the test results (8). Statistical significance should not be the only determining factor for a positive response. Equivocal results should be clarified by further testing preferably using a modification of experimental conditions.

A test substance for which the results do not meet the above criteria is considered non-mutagenic in this test.

Although most experiments will give clearly positive or negative results, in rare cases the data set will preclude making a definite judgement about the activity of the test substance. Results may remain equivocal or questionable regardless of the number of times the experiment is repeated.

Positive results from the in vivo spermatogonial chromosome aberration test indicate that the test substance induces structural chromosome aberrations in the germ cells of the species tested. Negative results indicate that, under the test conditions, the test substance does not induce chromosome aberrations in the germ cells of the species tested.

The likelihood that the test substance or its metabolites reach the target tissue should be discussed.

3. REPORTING

TEST REPORT

The test report must include the following information:

Solvent/vehicle:

— justification for choice of vehicle,

— solubility and stability of the test substance in solvent/vehicle, if known.

Test animals:

— species/strain used,

— number and age of animals,

— source, housing conditions, diet, etc.,

— individual weight of the animals at the start of the test, including body weight range, mean and standard deviation for each group.

Test conditions:

— data from range finding study, if concluded,

— rationale for dose level selection,

— rationale for route of administration,

— details of test substance preparation,

— details of the administration of the test substance,

— rationale for sacrifice times,
— conversion from diet/drinking water test substance concentration (ppm) to the actual dose (mg/kg body weight/day), if applicable,

— details of food and water quality,

— detailed description of treatment and sampling schedules,

— methods for measurement of toxicity,

— identity of metaphase arresting substance, its concentration and duration of treatment,

— methods of slide preparation,

— criteria for scoring aberrations,

— number of cells analysed per animal,

— criteria for considering studies as positive, negative or equivocal.

Results:

— signs of toxicity,

— mitotic index,

— ratio of spermatogonial mitoses cells to first and second meiotic metaphases,

— type and number of aberrations, given separately for each animal,

— total number of aberrations per group,

— number of cells with aberrations per group,

— dose-response relationship, if possible,

— statistical analyses, if any,

— concurrent negative control data,

— historical negative control data with ranges, means and standard deviations,

— concurrent positive control data,

— changes in ploidy, if seen.

Discussion of results.

Conclusions.

4. REFERENCES


ANNEX 4G

'B.39. UNSCHEDULED DNA SYNTHESIS (UDS) TEST WITH MAMMALIAN LIVER CELLS IN VIVO

1. METHOD

This method is a replicate of the OECD TG 486, Unscheduled DNA Synthesis (UDS) Test with Mammalian Liver Cells In Vivo (1997).

1.1. INTRODUCTION

The purpose of the unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo is to identify test substances that induce DNA repair in liver cells of treated animals (1), (2), (3), (4).

This in vivo test provides a method for investigating genotoxic effects of chemicals in the liver. The end point measured is indicative of DNA damage and subsequent repair in liver cells. The liver is usually the major site of metabolism of absorbed compounds. It is thus an appropriate site to measure DNA damage in vivo.

If there is evidence that the test substance will not reach the target tissue, it is not appropriate to use this test.

The end point of unscheduled DNA synthesis (UDS) is measured by determining the uptake of labelled nucleosides in cells that are not undergoing scheduled (S-phase) DNA synthesis. The most widely used technique is the determination of the uptake of tritium-labelled thymidine (3H-TdR) by autoradiography. Rat livers are preferably used for in vivo UDS tests. Tissues other than the livers may be used, but are not the subject of this method.

The detection of a UDS response is dependent on the number of DNA bases excised and replaced at the site of the damage. Therefore, the UDS test is particularly valuable to detect substance-induced "longpatch repair" (20 to 30 bases). In contrast "shortpatch repair" (one to three bases) is detected with much lower sensitivity. Furthermore, mutagenic events may result because of non-repair, misrepair or misreplication of DNA lesions.

The extent of the UDS response gives no indication of the fidelity of the repair process. In addition, it is possible that a mutagen reacts with DNA but the DNA damage is not repaired via an excision repair process. The lack of specific information on mutagenic activity provided by the UDS test is compensated for by the potential sensitivity of this end point because it is measured in the whole genome.

See also General Introduction Part B.

1.2. DEFINITIONS

Cells in repair: a net nuclear grain (NNG) higher than a preset value, to be justified at the laboratory conducting the test.

Net nuclear grains (NNG): quantitative measure for UDS activity of cells in autoradiographic UDS tests, calculated by subtracting the average number of cytoplasmic grains in nucleus-equivalent cytoplasmic areas (CG) from the number of nuclear grains (NG): NNG = NG - CG. NNG counts are calculated for individual cells and then pooled for cells in a culture, in parallel cultures, etc.

Unscheduled DNA synthesis (UDS): DNA repair synthesis after excision and removal of a stretch of DNA containing a region of damage induced by chemical substances or physical agents.

1.3. PRINCIPLE OF THE TEST METHOD

The UDS test with mammalian liver cells in vivo indicates DNA repair synthesis after excision and removal of a stretch of DNA containing a region of damage induced by chemical substances or physical agents. The test is usually based on the incorporation of 3H-TdR into the DNA of liver cells which have a low frequency of cells in the S-phase of the cell cycle. The uptake of 3H-TdR is usually determined by autoradiography, since this technique is not as susceptible to interference from S-phase cells as, for example, liquid scintillation counting.
1.4. DESCRIPTION OF THE METHOD

1.4.1. Preparations

1.4.1.1. Selections of animal species

Rats are commonly used, although any appropriate mammalian species may be used. Commonly used laboratory strains of young healthy adult animals should be employed. At the commencement of the study the weight variation of animals should be minimal and not exceed ± 20% of the mean weight for each sex.

1.4.1.2. Housing and feeding conditions

General conditions referred in the General Introduction to Part B are applied although the aim for humidity should be 50 to 60%.

1.4.1.3. Preparation of the animals

Healthy young adult animals are randomly assigned to the control and treatment groups. Cages should be arranged in such a way that possible effects due to cage placement are minimised. The animals are identified uniquely and kept in their cages for at least five days prior to the start of the study to allow for acclimatisation to the laboratory conditions.

1.4.1.4. Test substance/preparation

Solid test substances should be dissolved or suspended in appropriate solvents or vehicles and diluted, if appropriate, prior to dosing of the animals. Liquid test substances may be dosed directly or diluted prior to dosing. Fresh preparations of the test substance should be employed unless stability data demonstrate the acceptability of storage.

1.4.2. Test conditions

1.4.2.1. Solvent/vehicle

The solvent/vehicle should not produce toxic effects at the dose levels used, and should not be suspected of chemical reaction with the test substance. If other than well-known solvents/vehicles are used, their inclusion should be supported with data indicating their compatibility. It is recommended that wherever possible, the use of an aqueous solvent/vehicle should be considered first.

1.4.2.2. Controls

Concurrent positive and negative controls (solvent/vehicle) should be included in each independently performed part of the experiment. Except for treatment with the test substance, animals in the control group should be handled in an identical manner to the animals in the treated groups.

Positive controls should be substances known to produce UDS when administered at exposure levels expected to give a detectable increase over background. Positive controls needing metabolic activation should be used at doses eliciting a moderate response (4). The doses may be chosen so that the effects are clear but do not immediately reveal the identity of the coded slides to the reader. Examples of positive control substances include:

<table>
<thead>
<tr>
<th>Sampling times</th>
<th>Substance</th>
<th>CAS-No</th>
<th>EINECS No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early sampling times (2 to 4 hours)</td>
<td>N-nitrosodimethylamine</td>
<td>62-75-9</td>
<td>200-249-8</td>
</tr>
<tr>
<td>Late sampling times (12 to 16 hours)</td>
<td>N-2-fluorenylacetamide (2-AAF)</td>
<td>53-96-3</td>
<td>200-188-6</td>
</tr>
</tbody>
</table>

Other appropriate positive control substances may be used. It is acceptable that the positive control should be administered by a route different from the test substance.
1.5. PROCEDURE

1.5.1. Number and sex of animals

An adequate number of animals should be used to take account of natural biological variation in test response. The number of animal should be at least three analysable animals per group. Where a significant historical database has been accumulated, only one or two animals are required for the concurrent negative and positive control groups.

If at the time of the study there are data available from studies in the same species and using the same route of exposure that demonstrate that there are no substantial differences in toxicity between sexes, then testing in a single sex, preferably males, will be sufficient. Where human exposure to chemicals may be sex-specific, as for example with some pharmaceutical agents, the test should be performed with animals of the appropriate sex.

1.5.2. Treatment schedule

Test substances are generally administered as a single treatment.

1.5.3. Dose levels

Normally, at least two dose levels are used. The highest dose is defined as the dose producing signs of toxicity such that higher dose levels, based on the same dosing regimen, would be expected to produce lethality. In general, the lower dose should be 50% to 25% of the high dose.

Substances with specific biological activities at low non-toxic doses (such as hormones and mitogens) may be exceptions to the dose-setting criteria and should be evaluated on a case-by-case basis. If a range finding study is performed because there are no suitable data available, it should be performed in the same laboratory, using the same species, strain, sex, and treatment regimen to be used in the main study.

The highest dose may also be defined as a dose that produces some indication of toxicity in the liver (e.g. pyknotic nuclei).

1.5.4. Limit test

If a test at one dose level of at least 2 000 mg/kg body weight, applied in a single treatment, or in two treatments on the same day, produces no observable toxic effects, and if genotoxicity would not be expected, based upon data from structurally related substances, then a full study may not be necessary. Expected human exposure may indicate the need for a higher dose level to be used in the limit test.

1.5.5. Administration of doses

The test substance is usually administered by gavage using a stomach tube or a suitable intubation cannula. Other routes of exposure may be acceptable where they can be justified. However, the intraperitoneal route is not recommended as it could expose the liver directly to the test substance rather than via the circulatory system. The maximum volume of liquid that can be administered by gavage or injection at one time depends on the size of the test animal. The volume should not exceed 2 ml/100g body weight. The use of volumes higher than these must be justified. Except for irritating or corrosive substances, which will normally reveal exacerbated effects with higher concentrations, variability in test volume should be minimised by adjusting the concentration to ensure a constant volume at all dose levels.

1.5.6. Preparation of liver cells

Liver cells are prepared from treated animals normally 12 to 16 hours after dosing. An additional earlier sampling time (normally two to four hours post-treatment) is generally necessary unless there is a clear positive response at 12 to 16 hours. However, alternative sampling times may be used when justified on the basis of toxicokinetic data.
Short-term cultures of mammalian liver cells are usually established by perfusing the liver in situ with collagenase and allowing freshly dissociated liver cells to attach themselves to a suitable surface. Liver cells from negative control animals should have a viability (5) of at least 50%.

### 1.5.7. Determination of UDS

Freshly isolated mammalian liver cells are incubated usually with medium containing 3H-TdR for an appropriate length of time, e.g. three to eight hours. At the end of the incubation period, medium should be removed from the cells, which may then be incubated with medium containing excess unlabelled thymidine to diminish unincorporated radioactivity (“cold chase”). The cells are then rinsed, fixed and dried. For more prolonged incubation times, cold chase may not be necessary. Slides are dipped in autoradiographic emulsion, exposed in the dark (e.g. refrigerated for 7 to 14 days), developed, stained, and exposed silver grains are counted. Two to three slides are prepared from each animal.

### 1.5.8. Analysis

The slide preparations should contain sufficient cells of normal morphology to permit a meaningful assessment of UDS. Preparations are examined microscopically for signs of overt cytotoxicity (e.g. pyknosis, reduced levels of radiolabelling).

Slides should be coded before grain counting. Normally 100 cells are scored from each animal from at least two slides; the scoring of less than 100 cells/animals should be justified. Grain counts are not scored for S-phase nuclei, but the proportion of S-phase cells may be recorded.

The amount of 3H-TdR incorporation in the nuclei and the cytoplasm of morphologically normal cells, as evidenced by the deposition of silver grains, should be determined by suitable methods.

### 2. DATA

#### 2.1. TREATMENT OF RESULTS

Individual slide and animal data should be provided. Additionally, all data should be summarised in tabular form. Net nuclear grain (NNG) counts should be calculated for each cell, for each animal and for each dose and time by subtracting CG counts from NG counts. If “cells in repair” are counted, the criteria for defining “cells in repair” should be justified and based on historical or concurrent negative control data. Numerical results may be evaluated by statistical methods. If used, statistical tests should be selected and justified prior to conducting the study.

#### 2.2. EVALUATION AND INTERPRETATION OF RESULTS

Examples of criteria for positive/negative responses include:

- **positive**
  - (i) NNG values above a preset threshold which is justified on the basis of laboratory historical data;
  - or (ii) NNG values significantly greater than concurrent control;

- **negative**
  - (i) NNG values within/below historical control threshold;
  - or (ii) NNG values not significantly greater than concurrent control.

The biological relevance of data should be considered: i.e. parameters such as inter-animal variation, dose response relationship and cytotoxicity should be taken into account. Statistical methods may be used as an aid in evaluating the test results. However, statistical significance should not be the only determining factor for a positive response.
Although most experiments will give clearly positive or negative results, in rare cases the data set will preclude making a definite judgement about the activity of the test substance. Results may remain equivocal or questionable regardless of the number of times the experiment is repeated.

A positive result from the UDS test with mammalian liver cells in vivo indicates that a test substance induces DNA damage in mammalian liver cells in vivo that can be repaired by unscheduled DNA synthesis in vitro. A negative result indicates that, under the test conditions, the test substance does not induce DNA damage that is detectable by this test.

The likelihood that the test substance reaches the general circulation or specifically the target tissue (e.g. systemic toxicity) should be discussed.

3. REPORTING

TEST REPORT

The test report must include the following information.

Solvent vehicle:
- justification for choice of vehicle,
- solubility and stability of the test substance in solvent/vehicle, if known.

Test animals:
- species/strain used,
- number, age and sex of animals,
- source, housing conditions, diet, etc.,
- individual weight of the animals at the start of the test, including body weight range, mean and standard deviation for each group.

Test conditions:
- positive and negative vehicle/solvent controls,
- data from range-finding study, if conducted,
- rationale for dose level selection,
- details of test substance preparation,
- details of the administration of the test substance,
- rationale for route of administration,
- methods for verifying that test agent reached the general circulation or target tissue, if applicable,
- conversion from diet/drinking water test substance concentration (ppm) to the actual dose (mg/kg body weight/day), if applicable,
- details of food and water quality,
- detailed description of treatment and sampling schedules,
- methods for measurement of toxicity,
- method of liver cell preparation and culture,
- autoradiographic technique used,
— number of slides prepared and numbers of cells scored,
— evaluation criteria,
— criteria for considering studies as positive, negative or equivocal.

Results:
— individual slide, animal and group mean values for nuclear grains, cytoplasmic grains, and net nuclear grains,
— dose-response relationship, if available,
— statistical evaluation if any,
— signs of toxicity,
— concurrent negative (solvent/vehicle) and positive control data,
— historical negative (solvent/vehicle) and positive control data with range, means and standard deviations,
— number of "cells in repair" if determined,
— number of S-phase cells if determined,
— viability of the cells.

Discussion of results

Conclusions

4. REFERENCES


SV:

3.2.3. Farligt

R65 Farligt: kan ge lungskador vid förtäring.

Flytande ämnen och beredningar som på grund av sin läga viskositet utgör en fara för människa vid aspiration

a) För ämnen och beredningar som innehåller alifatiska, alicykliska och aromatiska kolväten i en total koncentration av 10% eller mer och
   — har en flödestid mindre än 30 sekunder, uppmätt med en 3 mm utloppsbägare enligt ISO 2431, eller
   — har en kinematisk viskositet lägre än \(7 \times 10^{-6} \text{ m}^2/\text{s}\) vid 40°C, uppmätt med en kalibrerad kapillarviskosimeter av glas, enligt ISO 3104 och ISO 3105, eller
   — har en kinematisk viskositet lägre än \(7 \times 10^{-6} \text{ m}^2/\text{s}\) vid 40°C, bestämd från rotationsviskosimetri enligt ISO 3219.

Ämnen och beredningar, som uppfyller dessa kriterier, behöver dock inte klassificeras om de har en genomsnittlig ytspänning högre än 33 mN/m vid 25°C, uppmätt med du Nouytensiometer eller enligt de testmetoder som finns beskrivna i bilaga V del A.5.

b) För ämnen och beredningar, baserat på praktiska erfarenheter från människa.

(Does not concern the ES version)
(Does not concern the DA version)
(Does not concern the DE version)
(Does not concern the EL version)
(Does not concern the EN version)
(Does not concern the FR version)
(Does not concern the IT version)
(Does not concern the NL version)
(Does not concern the PT version)
(Does not concern the FI version)

FI:

3.2.6.1 Ihon tulehtuminen

Seuraava vaaraa osoittava lauseka määräytyy alla esitetävien perusteitten mukaan:

R38 Ärsyttää ihoa

— Aineet ja valmisteet aiheuttavat ihon merkittävän tulehtumisen enintään neljän tunnin altistuksessa määritettyyn kallilla liitteessä V mainitulla ihoärsytstestillä. Tulehdus kestää vähintään 24 tuntia.

Ihon tulehdus on merkittävä, jos:

a) punoituksen ja ruvenmuodostuksen tai turvotuksen voimakkuutta kuvaavien lukuarvojen keskiarvo on vähintään 2;

b) tai kun liitteessä V tarkoitettua testiä on täydennetty käyttämällä kolmea koe-eläintä, vähintään kahden koe- eläimen ihon punoituksen ja ruvenmuodostuksen tai turvotuksen voimakkuutta kuvaavien lukuarvojen keskiarvo on, jokaiselle koe- eläimelle laskettuna erikseen, vähintään 2.

Kummassakin tapauksessa keskiarvojen laskemiseen on käytettävä kaikkia niitä lukuarvoja, jotka saadaan arvioitaessa vaikutusta 24 tunnin, 48 tunnin ja 72 tunnin välein.
Tulehdusta pidetään myös merkittävänä, jos ihon tulehtuminen jatkuu ainakin kahdella koe-eläimellä havainnointiajan päättymiseen asti. Erityiset vaikutukset kuten esimerkiksi hyperplasia, hilseileminen, varin muutokset, halkeamat, värin muutokset, ruvet ja karvojenlähtö on otettava huomioon.

Tähän liittyvää tietoa voidaan saada myös eläimillä tehtävistä ei-akuuttista altistuskokeista (katso lauseketta R48 koskevat huomautukset jaksossa 2.d). Vaikutuksia pidetään merkittävinä, jos ne vastaavat edellä kuvattuja vaikutuksia.

— Aineet ja valmisteet, jotka aiheuttavat ihmisillä merkittävää ihotulehdusta, kun koskus on ollut välitön, jatkuva tai toistuvaa.

— Orgaaniset peroksidit, paitsi jos on olemassa näyttöä siitä, että tallaista vaikutusta ei ole.

Tuntoharha (‘paresthesia’):

Pyretroiditorjunta-aineen ihokosketuksen aiheuttamaa tuntoharhaa ihmisessä ei pidetä ärsytysvaikutuksena, joka oikeuttaisi luokitukseen Xi; R38. S-lauseketta S24 on kuitenkin sovellettava aineisiin, joilla on tällainen vaikutus.

**In point 6.2 (Safety phrases for substances and preparations):**

**DE:**

**S 28 Bei Berührung mit der Haut sofort mit viel … abwaschen** (vom Hersteller anzugeben)

— Anwendungsbereich:

— sehr giftige, giftige oder ätzende Stoffe und Zubereitungen;

— Verwendung:

— obligatorisch für sehr giftige Stoffe und Zubereitungen;

— empfohlen für sonstige obengenannte Stoffe und Zubereitungen, insbesondere, wenn Wasser nicht die geeignete Spüflüssigkeit ist;

— empfohlen für ätzende Stoffe und Zubereitungen, die an die allgemeine Öffentlichkeit abgegeben werden.
S 29 Ei saa tyhjentää viemäriin

— Soveltamisala:
  — erittäin helposti syttyvät tai helposti syttyvät veteen sekoittumattomat nesteet,
  — erittäin myrkylliset tai myrkylliset aineet ja valmisteet,
  — ympäristölle vaaralliset aineet.

— Käytön perusteet:
  — pakollinen yleisessä kulutuksessa todennäköisesti käytettävälle ympäristölle vaarallisille ja tunnuksella N luokitelluille aineille, jollei kyseessä ole aineen tarkoitettu käyttö,
  — suositeltava yleisessä kulutuksessa todennäköisesti käytettävälle muille edellä mainituille aineille tai valmisteille, jollei kyseessä ole kemikaalin tarkoitettu käyttö.

(Does not concern the ES version)
(Does not concern the DA version)
(Does not concern the DE version)
(Does not concern the EL version)
(Does not concern the EN version)
(Does not concern the FR version)
(Does not concern the IT version)
(Does not concern the NL version)
(Does not concern the PT version)
(Does not concern the SV version)
ANNEX 6

ANNEX IX

PART A

Provisions relating to child-proof fastenings

In addition to the provisions in Article 22(1)(e) of this Directive, containers of whatever capacity containing substances presenting an aspiration hazard (Xn; R65) and classified and labelled according to paragraph 3.2.3 of Annex VI to this Directive, with the exception of substances placed on the market in the form of aerosols or in a container fitted with a sealed spray attachment, shall be fitted with child-proof fastenings.

1. Reclosable packages


2. Non-reclosable packages

Child-proof fastenings used on non-reclosable packages shall comply with CEN standard EN 862 (March 1997 edition) relating to “Packaging — Child-resistant packaging — Requirements and testing procedures for non-reclosable packages for non-pharmaceutical products” adopted by the European Committee for Standardisation (CEN).

3. Notes

1. Evidence of conformity with the above standards may be certified only by laboratories which conform with European Standards Series EN 45 000.

2. Specific cases

If it seems obvious that packaging is sufficiently safe for children because they cannot get access to the contents without the help of a tool, the test does not need to be performed.

In all other cases and when there are sufficient grounds for doubting the security of the closure for a child, the national authority may ask the person responsible for putting the product on the market to give it a certificate from a laboratory, described in 3.1, stating that either:

— the type of closure is such that it is not necessary to test to the ISO and CEN standards referred to above, or

— the closure has been tested and has been found to conform with the standards referred to above.

PART B

Provisions relating to tactile warning devices


__________________________________________________________________________